Gene	"Gene synonym"	Ensembl	"Gene description"	Uniprot	Chromosome	Position	"Protein class"	"Biological process"	"Molecular function"	"Disease involvement"	Evidence	"HPA evidence"	"UniProt evidence"	"NeXtProt evidence"	"MS evidence"	"RNA tissue specificity"	"RNA tissue distribution"	"RNA tissue specificity score"	"RNA tissue specific NX"	"RNA cell line specificity"	"RNA cell line distribution"	"RNA cell line specificity score"	"RNA cell line specific NX"	"RNA cancer specificity"	"RNA cancer distribution"	"RNA cancer specificity score"	"RNA cancer specific FPKM"	"RNA brain regional specificity"	"RNA brain regional distribution"	"RNA brain regional specificity score"	"RNA brain regional specific NX"	"RNA blood cell specificity"	"RNA blood cell distribution"	"RNA blood cell specificity score"	"RNA blood cell specific NX"	"RNA blood lineage specificity"	"RNA blood lineage distribution"	"RNA blood lineage specificity score"	"RNA blood lineage specific NX"	"RNA mouse brain regional specificity"	"RNA mouse brain regional distribution"	"RNA mouse brain regional specificity score"	"RNA mouse brain regional specific pTPM"	"RNA pig brain regional specificity"	"RNA pig brain regional distribution"	"RNA pig brain regional specificity score"	"RNA pig brain regional specific pTPM"	Antibody	"Reliability (IH)"	"Reliability (Mouse Brain)"	"Reliability (IF)"	"Subcellular location"	"Secretome location"	"Blood concentration - Conc. blood IM [pg/L]"	"Blood concentration - Conc. blood MS [pg/L]"	"Subcellular main location"	"Subcellular additional location"	"Antibody RRID"	"Pathology prognostics - Breast cancer"	"Pathology prognostics - Cervical cancer"	"Pathology prognostics - Colorectal cancer"	"Pathology prognostics - Endometrial cancer"	"Pathology prognostics - Glioma"	"Pathology prognostics - Head and neck cancer"	"Pathology prognostics - Liver cancer"	"Pathology prognostics - Lung cancer"	"Pathology prognostics - Melanoma"	"Pathology prognostics - Ovarian cancer"	"Pathology prognostics - Pancreatic cancer"	"Pathology prognostics - Prostate cancer"	"Pathology prognostics - Renal cancer"	"Pathology prognostics - Stomach cancer"	"Pathology prognostics - Testis cancer"	"Pathology prognostics - Thyroid cancer"	"Pathology prognostics - Urothelial cancer"	"Tissue RNA - adipose tissue [NX]"	"Tissue RNA - adrenal gland [NX]"	"Tissue RNA - amygdala [NX]"	"Tissue RNA - appendix [NX]"	"Tissue RNA - basal ganglia [NX]"	"Tissue RNA - bone marrow [NX]"	"Tissue RNA - breast [NX]"	"Tissue RNA - cerebellum [NX]"	"Tissue RNA - cerebral cortex [NX]"	"Tissue RNA - cervix, uterine [NX]"	"Tissue RNA - colon [NX]"	"Tissue RNA - corpus callosum [NX]"	"Tissue RNA - ductus deferens [NX]"	"Tissue RNA - duodenum [NX]"	"Tissue RNA - endometrium 1 [NX]"	"Tissue RNA - epididymis [NX]"	"Tissue RNA - esophagus [NX]"	"Tissue RNA - fallopian tube [NX]"	"Tissue RNA - gallbladder [NX]"	"Tissue RNA - heart muscle [NX]"	"Tissue RNA - hippocampal formation [NX]"	"Tissue RNA - hypothalamus [NX]"	"Tissue RNA - kidney [NX]"	"Tissue RNA - liver [NX]"	"Tissue RNA - lung [NX]"	"Tissue RNA - lymph node [NX]"	"Tissue RNA - midbrain [NX]"	"Tissue RNA - olfactory region [NX]"	"Tissue RNA - ovary [NX]"	"Tissue RNA - pancreas [NX]"	"Tissue RNA - parathyroid gland [NX]"	"Tissue RNA - pituitary gland [NX]"	"Tissue RNA - placenta [NX]"	"Tissue RNA - pons and medulla [NX]"	"Tissue RNA - prostate [NX]"	"Tissue RNA - rectum [NX]"	"Tissue RNA - retina [NX]"	"Tissue RNA - salivary gland [NX]"	"Tissue RNA - seminal vesicle [NX]"	"Tissue RNA - skeletal muscle [NX]"	"Tissue RNA - skin 1 [NX]"	"Tissue RNA - small intestine [NX]"	"Tissue RNA - smooth muscle [NX]"	"Tissue RNA - spinal cord [NX]"	"Tissue RNA - spleen [NX]"	"Tissue RNA - stomach 1 [NX]"	"Tissue RNA - testis [NX]"	"Tissue RNA - thalamus [NX]"	"Tissue RNA - thymus [NX]"	"Tissue RNA - thyroid gland [NX]"	"Tissue RNA - tongue [NX]"	"Tissue RNA - tonsil [NX]"	"Tissue RNA - urinary bladder [NX]"	"Tissue RNA - vagina [NX]"	"Tissue RNA - B-cells [NX]"	"Tissue RNA - dendritic cells [NX]"	"Tissue RNA - granulocytes [NX]"	"Tissue RNA - monocytes [NX]"	"Tissue RNA - NK-cells [NX]"	"Tissue RNA - T-cells [NX]"	"Tissue RNA - total PBMC [NX]"	"Cell RNA - A-431 [NX]"	"Cell RNA - A549 [NX]"	"Cell RNA - AF22 [NX]"	"Cell RNA - AN3-CA [NX]"	"Cell RNA - ASC diff [NX]"	"Cell RNA - ASC TERT1 [NX]"	"Cell RNA - BEWO [NX]"	"Cell RNA - BJ [NX]"	"Cell RNA - BJ hTERT+ [NX]"	"Cell RNA - BJ hTERT+ SV40 Large T+ [NX]"	"Cell RNA - BJ hTERT+ SV40 Large T+ RasG12V [NX]"	"Cell RNA - CACO-2 [NX]"	"Cell RNA - CAPAN-2 [NX]"	"Cell RNA - Daudi [NX]"	"Cell RNA - EFO-21 [NX]"	"Cell RNA - fHDF/TERT166 [NX]"	"Cell RNA - HaCaT [NX]"	"Cell RNA - HAP1 [NX]"	"Cell RNA - HBEC3-KT [NX]"	"Cell RNA - HBF TERT88 [NX]"	"Cell RNA - HDLM-2 [NX]"	"Cell RNA - HEK 293 [NX]"	"Cell RNA - HEL [NX]"	"Cell RNA - HeLa [NX]"	"Cell RNA - Hep G2 [NX]"	"Cell RNA - HHSteC [NX]"	"Cell RNA - HL-60 [NX]"	"Cell RNA - HMC-1 [NX]"	"Cell RNA - HSkMC [NX]"	"Cell RNA - hTCEpi [NX]"	"Cell RNA - hTEC/SVTERT24-B [NX]"	"Cell RNA - hTERT-HME1 [NX]"	"Cell RNA - HUVEC TERT2 [NX]"	"Cell RNA - K-562 [NX]"	"Cell RNA - Karpas-707 [NX]"	"Cell RNA - LHCN-M2 [NX]"	"Cell RNA - MCF7 [NX]"	"Cell RNA - MOLT-4 [NX]"	"Cell RNA - NB-4 [NX]"	"Cell RNA - NTERA-2 [NX]"	"Cell RNA - PC-3 [NX]"	"Cell RNA - REH [NX]"	"Cell RNA - RH-30 [NX]"	"Cell RNA - RPMI-8226 [NX]"	"Cell RNA - RPTEC TERT1 [NX]"	"Cell RNA - RT4 [NX]"	"Cell RNA - SCLC-21H [NX]"	"Cell RNA - SH-SY5Y [NX]"	"Cell RNA - SiHa [NX]"	"Cell RNA - SK-BR-3 [NX]"	"Cell RNA - SK-MEL-30 [NX]"	"Cell RNA - T-47d [NX]"	"Cell RNA - THP-1 [NX]"	"Cell RNA - TIME [NX]"	"Cell RNA - U-138 MG [NX]"	"Cell RNA - U-2 OS [NX]"	"Cell RNA - U-2197 [NX]"	"Cell RNA - U-251 MG [NX]"	"Cell RNA - U-266/70 [NX]"	"Cell RNA - U-266/84 [NX]"	"Cell RNA - U-698 [NX]"	"Cell RNA - U-87 MG [NX]"	"Cell RNA - U-937 [NX]"	"Cell RNA - WM-115 [NX]"	"Blood RNA - basophil [NX]"	"Blood RNA - classical monocyte [NX]"	"Blood RNA - eosinophil [NX]"	"Blood RNA - gdT-cell [NX]"	"Blood RNA - intermediate monocyte [NX]"	"Blood RNA - MAIT T-cell [NX]"	"Blood RNA - memory B-cell [NX]"	"Blood RNA - memory CD4 T-cell [NX]"	"Blood RNA - memory CD8 T-cell [NX]"	"Blood RNA - myeloid DC [NX]"	"Blood RNA - naive B-cell [NX]"	"Blood RNA - naive CD4 T-cell [NX]"	"Blood RNA - naive CD8 T-cell [NX]"	"Blood RNA - neutrophil [NX]"	"Blood RNA - NK-cell [NX]"	"Blood RNA - non-classical monocyte [NX]"	"Blood RNA - plasmacytoid DC [NX]"	"Blood RNA - T-reg [NX]"	"Blood RNA - total PBMC [NX]"	"Brain RNA - amygdala [NX]"	"Brain RNA - basal ganglia [NX]"	"Brain RNA - cerebellum [NX]"	"Brain RNA - cerebral cortex [NX]"	"Brain RNA - hippocampal formation [NX]"	"Brain RNA - hypothalamus [NX]"	"Brain RNA - midbrain [NX]"	"Brain RNA - olfactory region [NX]"	"Brain RNA - pons and medulla [NX]"	"Brain RNA - thalamus [NX]"
AGRP	"Agrt, ART, ASIP2"	ENSG00000159723	"Agouti related neuropeptide"	O00253	16	67482571-67483813	"Disease related genes, Plasma proteins, Predicted secreted proteins"			"Disease mutation, Obesity"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"brain: 19.4;epididymis: 49.8"	"Cell line enhanced"	"Detected in some"		"CACO-2: 2.6;CAPAN-2: 2.7;HeLa: 1.5;Hep G2: 2.1;HMC-1: 1.8"	"Low cancer specificity"	"Detected in single"			"Region enriched"	"Detected in some"	13	"hypothalamus: 19.4"	"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Region enriched"	"Detected in single"	16	"hypothalamus: 18.9"	"Region enhanced"	"Detected in some"		"hypothalamus: 3.9"	HPA041017	Enhanced	Supported			"Secreted in other tissues"					"HPA041017: AB_10795498"	"unprognostic (1.32e-1)"	"unprognostic (6.26e-2)"	"unprognostic (1.13e-1)"	"unprognostic (4.16e-1)"	"unprognostic (3.15e-1)"	"unprognostic (1.10e-1)"	"unprognostic (3.61e-1)"	"unprognostic (3.34e-1)"	"unprognostic (4.68e-1)"	"unprognostic (1.29e-1)"	"unprognostic (6.74e-2)"	"unprognostic (3.17e-1)"	"unprognostic (2.80e-1)"	"unprognostic (1.72e-1)"	"unprognostic (5.63e-2)"	"unprognostic (1.09e-1)"	"unprognostic (1.18e-2)"	0.1	9.6	0.1	0.1	1.4	0.0	0.1	0.1	0.2	0.1	0.1	0.3	0.1	0.0	0.1	49.8	0.1	0.0	0.1	0.1	0.1	19.4	0.5	0.1	2.1	0.3	0.1	0.3	0.1	0.1	0.0	0.4	0.1	0.2	0.1	0.0	0.3	0.5	0.1	0.1	0.4	0.1	0.1	0.3	0.3	0.1	1.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	2.2	2.1	1.4	3.8	0.3	3.2	1.0	0.1	0.0	0.4	1.4	0.0	0.0	0.6	0.0	0.0	0.0	0.0	2.6	2.7	0.8	0.2	0.0	0.3	0.3	0.0	0.0	0.0	0.0	0.4	1.5	2.1	0.0	0.0	1.8	0.6	0.0	0.0	0.0	0.0	0.1	0.9	0.0	0.0	0.2	0.5	0.0	0.0	0.0	0.0	0.3	0.3	0.7	0.0	0.1	0.0	0.0	0.0	0.2	0.3	0.0	0.5	0.2	0.0	0.1	1.0	0.5	0.9	0.0	0.4	0.3	0.0	3.8	1.4	3.2	2.3	1.6	2.2	0.8	1.1	1.5	1.9	2.1	2.2	0.6	0.3	1.2	2.1	1.3	1.0	0.1	1.4	0.1	0.2	0.1	19.4	0.1	0.3	0.2	0.1
AKR1B1	"ALDR1, AR"	ENSG00000085662	"Aldo-keto reductase family 1 member B"	P15121	7	134442350-134459284	"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins"		Oxidoreductase	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in all"	4	"adrenal gland: 302.2;seminal vesicle: 109.3"	"Cell line enhanced"	"Detected in many"		"A549: 121.0;BJ hTERT+: 222.0;RPTEC TERT1: 105.0;U-87 MG: 99.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA026425, CAB027391, CAB047353, HPA052751"	Enhanced		Supported	Nucleoplasm,Cytosol			1700000	Cytosol	Nucleoplasm	"CAB027391: , CAB047353: , HPA026425: AB_10601563, HPA052751: "	"unprognostic (2.76e-2)"	"unprognostic (2.84e-2)"	"unprognostic (2.02e-2)"	"unprognostic (1.37e-2)"	"unprognostic (6.81e-2)"	"unprognostic (2.26e-1)"	"unprognostic (4.18e-2)"	"unprognostic (5.09e-2)"	"unprognostic (2.51e-3)"	"unprognostic (2.47e-1)"	"unprognostic (2.98e-2)"	"unprognostic (8.78e-2)"	"unprognostic (2.81e-2)"	"prognostic unfavourable (2.44e-5)"	"unprognostic (2.03e-1)"	"unprognostic (1.39e-1)"	"prognostic unfavourable (7.00e-4)"	5.9	302.2	7.5	4.7	13.7	2.5	9.5	6.9	10.9	4.4	3.9	8.2	50.4	2.7	4.6	6.1	4.2	4.6	5.2	24.2	7.3	8.4	17.7	2.5	6.9	10.0	9.5	9.0	8.2	7.2	9.4	8.0	24.8	11.9	5.5	4.1	5.8	4.4	109.3	37.6	2.8	4.8	5.6	7.9	6.7	5.0	5.2	5.9	7.3	6.0	10.3	7.6	7.1	3.7	31.4	34.8	22.5	26.0	26.3	42.7	47.2	13.3	121.0	13.6	19.3	58.9	16.0	36.3	13.0	222.0	19.1	24.8	5.6	12.3	0.0	6.0	21.7	5.7	14.8	12.9	15.2	4.8	13.6	6.8	18.2	16.4	84.4	0.0	0.0	14.9	9.7	27.3	7.3	26.9	0.0	4.5	21.1	0.2	20.0	9.2	22.7	0.1	20.9	8.7	10.1	105.0	65.4	10.2	22.7	90.9	0.1	9.5	0.0	10.2	21.2	18.9	8.8	1.7	14.1	12.5	13.7	33.8	99.9	0.0	11.3	22.5	26.0	1.2	37.9	17.0	34.0	31.4	32.4	36.7	34.8	28.5	42.7	41.1	2.1	26.3	8.9	4.9	22.0	47.2	7.5	13.7	6.9	10.9	7.3	8.4	9.5	9.0	11.9	5.9
ARHGAP36	FLJ30058	ENSG00000147256	"Rho GTPase activating protein 36"	Q6ZRI8	X	131058242-131089883	"Predicted intracellular proteins"		"GTPase activation"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"adrenal gland: 58.4;brain: 25.5;pituitary gland: 50.3"	"Cell line enriched"	"Detected in single"	164	"SH-SY5Y: 62.9"	"Cancer enriched"	"Detected in some"	21	"thyroid cancer: 62.5"	"Region enriched"	"Detected in many"	5	"hypothalamus: 25.5"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Region enhanced"	"Detected in many"		"hypothalamus: 104.3"	"Group enriched"	"Detected in many"	5	"basal ganglia: 19.8;hypothalamus: 57.8;midbrain: 27.1;pons and medulla: 20.1"	"HPA002064, HPA076209"	Enhanced		Approved	"Nucleoplasm,Vesicles,Plasma membrane"				Nucleoplasm	"Vesicles, Plasma membrane"	"HPA002064: AB_1078891, HPA076209: "	"unprognostic (2.92e-2)"			"unprognostic (7.71e-9)"	"unprognostic (2.19e-1)"	"unprognostic (8.15e-2)"				"unprognostic (1.67e-1)"	"unprognostic (1.78e-1)"	"unprognostic (2.73e-1)"		"unprognostic (1.40e-2)"	"unprognostic (1.34e-2)"	"unprognostic (2.31e-1)"		6.9	58.4	1.4	0.2	3.6	0.1	1.0	0.0	2.7	0.5	0.2	0.0	0.0	0.1	0.1	2.0	0.3	0.2	0.2	0.1	1.0	25.5	0.1	0.1	0.1	0.1	0.5	0.0	0.1	0.1	0.1	50.3	0.3	5.4	0.3	0.2	0.6	0.2	0.2	13.7	0.1	0.1	0.1	0.8	0.1	0.2	0.6	0.0	0.5	0.5	4.0	0.5	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.1	62.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.4	3.6	0.0	0.4	1.0	25.5	0.5	0.0	5.4	0.0
AS3MT	CYT19	ENSG00000214435	"Arsenite methyltransferase"	Q9HBK9	10	102869516-102901899	"Enzymes, Predicted intracellular proteins"		"Methyltransferase, Transferase"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"adrenal gland: 92.8;parathyroid gland: 30.0"	"Cell line enhanced"	"Detected in many"		"AF22: 14.2;REH: 27.1;SH-SY5Y: 14.6;T-47d: 22.7"	"Cancer enhanced"	"Detected in single"		"liver cancer: 1.0"	"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in single"	6	"NK-cell: 1.4"	"Lineage enriched"	"Detected in single"	6	"NK-cells: 1.4"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA017856	Enhanced		Approved	Mitochondria				Mitochondria		"HPA017856: AB_1847420"	"unprognostic (1.11e-1)"	"unprognostic (2.02e-4)"	"unprognostic (2.45e-1)"	"unprognostic (2.25e-1)"	"unprognostic (3.39e-1)"	"unprognostic (1.66e-1)"	"unprognostic (7.02e-4)"	"unprognostic (3.22e-1)"	"unprognostic (1.42e-1)"	"unprognostic (3.90e-2)"	"unprognostic (2.03e-1)"	"unprognostic (1.83e-1)"	"unprognostic (3.83e-10)"	"unprognostic (1.04e-2)"	"unprognostic (4.17e-2)"	"unprognostic (1.59e-1)"	"unprognostic (2.16e-2)"	2.0	92.8	3.7	0.7	8.6	0.5	2.6	4.5	6.4	4.0	2.0	2.2	0.4	1.3	3.8	3.2	2.1	2.1	5.2	10.0	5.7	3.1	7.4	22.4	1.7	0.9	2.8	4.4	3.9	8.7	30.0	2.4	0.5	4.6	4.2	0.8	8.9	2.2	3.4	6.0	1.8	1.3	3.9	2.7	5.6	1.7	3.5	1.6	0.3	3.2	1.0	0.7	1.8	1.8	0.0	0.0	0.0	0.0	1.4	0.2	0.0	0.0	3.9	14.2	8.9	0.3	0.3	2.6	4.1	3.5	6.2	7.6	10.6	0.6	0.2	1.2	5.3	0.2	12.1	0.7	6.4	0.0	3.5	0.0	1.7	10.4	4.1	0.2	0.1	1.9	1.6	0.8	0.0	0.2	0.0	0.2	5.5	0.1	2.4	0.3	6.8	0.6	27.1	0.0	0.1	1.3	0.1	0.4	14.6	0.0	0.2	1.9	22.7	0.3	0.1	1.3	0.0	2.0	0.0	0.3	0.2	0.0	4.5	0.1	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.4	0.0	0.0	0.0	0.0	3.7	8.6	4.5	6.4	5.7	3.1	2.8	4.4	4.6	1.6
CALY	"CALCYON, DRD1IP, NSG3"	ENSG00000130643	"Calcyon neuron specific vesicular protein"	Q9NYX4	10	133324072-133336935	"FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"	Endocytosis		"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	9	"adrenal gland: 26.5;brain: 98.9;pituitary gland: 47.7"	"Cell line enhanced"	"Detected in some"		"SH-SY5Y: 2.7;U-266/70: 2.6"	"Group enriched"	"Detected in some"	14	"glioma: 1.7;pancreatic cancer: 7.7"	"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"memory CD8 T-cell: 1.3;naive CD4 T-cell: 1.0"	"Lineage enriched"	"Detected in single"	14	"T-cells: 1.3"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA042283	Enhanced									"HPA042283: AB_10794417"	"unprognostic (1.43e-2)"	"unprognostic (7.84e-2)"	"unprognostic (3.77e-3)"	"unprognostic (1.41e-2)"	"unprognostic (7.32e-2)"	"unprognostic (9.81e-3)"	"unprognostic (2.56e-1)"	"unprognostic (7.48e-2)"	"unprognostic (1.36e-1)"	"unprognostic (1.18e-1)"	"prognostic favourable (3.54e-4)"	"unprognostic (1.23e-2)"	"unprognostic (4.19e-10)"	"unprognostic (8.04e-3)"	"unprognostic (1.29e-1)"	"unprognostic (3.60e-1)"	"unprognostic (1.63e-1)"	1.8	26.5	27.1	2.7	57.4	1.8	1.8	12.7	67.1	1.7	2.6	3.6	0.0	5.0	1.7	1.9	1.8	2.0	1.8	1.7	31.8	98.9	1.7	1.7	1.9	2.0	25.1	39.8	1.7	6.3	1.7	47.7	1.7	33.9	1.8	2.4	0.7	2.1	2.0	1.7	1.9	3.8	2.1	14.3	1.9	4.1	4.3	4.8	0.0	1.9	0.0	1.9	1.7	0.0	0.0	0.0	0.0	0.0	0.0	1.3	0.6	0.1	0.8	0.3	0.0	0.0	0.0	0.3	0.6	0.6	0.0	0.0	0.0	0.0	0.5	0.5	0.0	0.1	0.3	0.0	0.0	0.3	0.0	0.1	0.0	0.8	1.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.1	1.0	0.0	1.1	0.0	0.0	0.3	0.0	0.0	0.4	0.1	0.0	0.0	0.0	2.7	0.0	0.0	0.9	0.1	0.0	0.0	0.0	0.3	0.0	0.1	2.6	0.0	0.0	0.3	0.2	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	1.3	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	27.1	57.4	12.7	45.9	31.8	98.9	25.1	39.8	33.9	4.8
CARTPT	CART	ENSG00000164326	"CART prepropeptide"	Q16568	5	71719163-71721048	"FDA approved drug targets, Predicted secreted proteins"		"Neuropeptide, Neurotransmitter"	"FDA approved drug targets, Obesity"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	10	"adrenal gland: 67.5;brain: 101.4"	"Group enriched"	"Detected in some"	7	"NB-4: 1.0;SH-SY5Y: 3.4"	"Cancer enriched"	"Detected in many"	9	"breast cancer: 117.7"	"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			"Region enhanced"	"Detected in many"		"hippocampal formation: 179.9"	"CAB025515, HPA046278, CAB079776"	Enhanced	Supported			"Secreted to blood"					"CAB025515: , CAB079776: , HPA046278: AB_10961570"			"unprognostic (1.37e-1)"		"unprognostic (1.43e-1)"					"unprognostic (2.27e-1)"	"unprognostic (3.45e-2)"	"unprognostic (6.67e-2)"		"prognostic unfavourable (4.36e-4)"		"unprognostic (1.14e-1)"		1.6	67.5	8.0	2.8	22.3	0.5	5.8	0.1	29.0	0.5	3.4	2.1	0.0	3.5	0.6	0.9	3.5	0.7	0.6	0.5	31.1	101.4	0.5	0.5	0.5	0.5	1.0	4.5	0.5	5.3	0.5	1.7	0.5	54.1	3.3	3.1	1.6	0.5	0.5	0.5	0.5	1.4	8.1	8.6	0.5	3.4	1.9	9.7	0.0	3.4	0.0	0.5	0.5	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	3.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	8.0	22.3	0.1	29.0	31.1	101.4	1.0	4.5	54.1	9.7
CHGB	"SCG1, SgI"	ENSG00000089199	"Chromogranin B"	P05060	20	5911430-5925361	"Plasma proteins, Predicted intracellular proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"adrenal gland: 424.9;pituitary gland: 177.5"	"Group enriched"	"Detected in some"	23	"SCLC-21H: 65.1;SH-SY5Y: 99.7"	"Cancer enriched"	"Detected in many"	6	"pancreatic cancer: 154.2"	"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in some"		"memory CD4 T-cell: 2.6;T-reg: 1.1"	"Lineage enhanced"	"Detected in single"		"T-cells: 2.6"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA008759, CAB009403, HPA012602"	Enhanced	Supported	Enhanced	Vesicles	"Intracellular and membrane"		24000000	Vesicles		"CAB009403: AB_2081255, HPA008759: AB_1846704, HPA012602: AB_1846706"	"unprognostic (1.79e-3)"	"unprognostic (7.72e-2)"	"unprognostic (3.48e-1)"	"unprognostic (2.90e-2)"	"unprognostic (1.68e-2)"	"prognostic unfavourable (1.89e-4)"	"unprognostic (7.96e-3)"	"unprognostic (2.86e-1)"	"unprognostic (6.18e-3)"	"unprognostic (7.93e-2)"	"prognostic favourable (9.96e-4)"	"unprognostic (8.56e-2)"	"unprognostic (8.21e-2)"	"unprognostic (1.56e-1)"	"unprognostic (2.81e-2)"	"unprognostic (2.73e-1)"	"unprognostic (1.01e-2)"	3.4	424.9	8.2	1.4	10.2	0.8	1.0	82.5	16.4	0.8	3.0	2.1	1.2	7.7	0.9	1.3	0.8	2.5	0.8	7.6	20.7	15.4	1.7	0.7	1.0	1.1	7.2	9.1	3.0	17.0	0.8	177.5	0.8	51.8	5.6	2.5	0.7	0.9	1.2	2.1	0.9	4.4	0.9	2.3	0.8	19.7	2.4	0.8	0.0	1.9	0.4	0.9	0.8	0.1	0.0	0.6	0.0	0.0	0.0	2.6	0.2	0.0	1.4	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.4	0.0	0.2	0.0	0.7	0.0	0.2	0.0	0.0	0.3	0.0	0.0	0.0	0.1	0.0	0.0	0.1	3.5	0.0	0.0	0.0	0.0	0.0	0.0	65.1	99.7	0.0	0.1	0.0	0.0	0.0	0.0	0.0	1.1	0.0	0.5	0.0	0.1	0.4	0.1	0.5	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.6	0.0	0.6	0.0	0.2	0.0	0.0	0.0	0.0	0.0	1.1	0.2	8.2	10.2	82.5	16.4	20.7	15.4	7.2	9.1	51.8	0.8
CPLX1	CPX-I	ENSG00000168993	"Complexin 1"	O14810	4	784957-826198	"Predicted intracellular proteins"	"Exocytosis, Neurotransmitter transport, Transport"		"Disease mutation, Epilepsy"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	13	"brain: 98.8"	"Cell line enriched"	"Detected in some"	5	"SCLC-21H: 42.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in single"		"plasmacytoid DC: 2.3"	"Low lineage specificity"	"Detected in single"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA071191, HPA074390"	Supported		Uncertain	Vesicles				Vesicles		"HPA071191: , HPA074390: "	"unprognostic (9.21e-3)"	"prognostic unfavourable (4.20e-4)"	"unprognostic (3.45e-2)"	"unprognostic (4.68e-2)"	"unprognostic (1.16e-2)"	"unprognostic (1.02e-1)"	"unprognostic (3.14e-2)"	"unprognostic (2.26e-2)"	"unprognostic (9.52e-3)"	"unprognostic (2.01e-2)"	"prognostic favourable (5.05e-4)"	"unprognostic (1.10e-3)"	"unprognostic (3.32e-1)"	"unprognostic (2.05e-2)"	"unprognostic (1.12e-1)"	"unprognostic (1.34e-1)"	"unprognostic (7.77e-2)"	7.8	6.5	13.1	2.9	40.7	1.5	2.4	26.3	98.8	2.2	2.5	3.9	0.0	2.8	4.2	1.5	1.6	2.3	1.9	3.0	16.9	7.6	2.4	2.4	2.8	2.4	16.3	18.3	2.4	3.0	3.4	1.7	1.8	52.8	4.4	1.7	3.8	4.4	2.5	4.5	3.0	2.8	2.0	5.4	5.6	3.2	4.9	4.2	0.0	1.8	0.0	1.6	1.7	1.7	0.2	2.3	0.1	0.0	0.0	0.8	0.0	2.7	0.2	0.0	0.4	0.0	0.0	0.1	0.1	0.0	0.0	0.0	8.0	0.8	2.0	0.9	0.0	0.0	0.2	0.0	0.0	0.0	0.9	0.2	0.0	0.8	0.0	0.0	0.2	0.3	0.0	0.0	0.0	0.0	0.9	0.1	0.0	1.1	1.1	0.0	1.3	1.3	0.0	0.0	0.7	0.0	0.2	42.0	5.8	0.2	2.7	0.0	4.2	0.1	0.0	0.0	0.2	0.0	0.0	0.1	2.1	0.0	0.0	0.1	0.1	0.1	0.0	0.0	0.0	0.0	0.8	0.0	0.3	0.1	0.0	0.2	0.0	0.0	0.0	0.0	0.0	2.3	0.0	0.0	13.1	40.7	26.3	98.8	16.9	7.6	16.3	18.3	52.8	4.2
CPLX2	"CPX-2, DKFZp547D155"	ENSG00000145920	"Complexin 2"	Q6PUV4	5	175796310-175884020	"Predicted intracellular proteins"	"Differentiation, Exocytosis, Mast cell degranulation, Neurogenesis, Neurotransmitter transport, Transport"			"Evidence at protein level"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 95.3;epididymis: 80.1"	"Group enriched"	"Detected in some"	22	"A549: 103.7;Hep G2: 62.5;SCLC-21H: 44.1"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in single"	4	"MAIT T-cell: 1.2"	"Lineage enriched"	"Detected in single"	13	"T-cells: 1.2"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA071191, HPA074390"	Supported		Uncertain	Vesicles				Vesicles		"HPA071191: , HPA074390: "	"unprognostic (1.36e-1)"	"unprognostic (1.12e-1)"	"unprognostic (2.81e-1)"	"unprognostic (8.98e-2)"	"unprognostic (1.23e-2)"	"unprognostic (5.73e-2)"	"unprognostic (5.16e-2)"	"unprognostic (2.49e-3)"		"unprognostic (6.22e-2)"	"unprognostic (1.20e-2)"	"unprognostic (2.06e-1)"	"unprognostic (1.90e-5)"	"unprognostic (6.88e-2)"	"unprognostic (2.20e-1)"	"unprognostic (7.32e-2)"	"unprognostic (6.87e-2)"	1.7	23.3	72.6	2.0	32.7	1.4	1.3	79.0	95.3	1.3	2.6	2.6	0.3	2.7	1.3	80.1	1.4	1.4	1.4	1.3	68.3	16.3	1.4	1.3	2.1	1.3	37.2	26.3	1.3	7.9	1.3	11.3	1.3	17.9	1.4	2.2	0.2	1.3	1.4	1.3	1.4	2.5	1.6	4.0	1.3	5.1	3.1	3.7	0.0	1.4	0.0	1.3	1.5	0.0	0.0	0.0	0.0	0.0	0.0	1.2	0.0	0.0	103.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	62.5	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.4	0.0	0.0	0.0	0.1	0.0	0.0	44.1	3.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2	0.0	0.1	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.2	0.0	72.6	32.7	79.0	66.6	68.3	16.3	37.2	26.3	17.9	3.7
CYP11A1	"CYP11A, P450SCC"	ENSG00000140459	"Cytochrome P450 family 11 subfamily A member 1"	P05108	15	74337759-74367740	"Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins"	"Cholesterol metabolism, Lipid biosynthesis, Lipid metabolism, Steroid biosynthesis, Steroid metabolism, Steroidogenesis, Sterol metabolism"	"Monooxygenase, Oxidoreductase"	"Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	7	"adrenal gland: 145.3;placenta: 157.2"	"Group enriched"	"Detected in some"	4	"BEWO: 43.1;HEL: 34.2"	"Low cancer specificity"	"Detected in many"			"Region enriched"	"Detected in single"	36	"basal ganglia: 14.8"	"Cell type enriched"	"Detected in single"	37	"basophil: 15.8"	"Lineage enriched"	"Detected in single"	37	"granulocytes: 15.8"	"Low region specificity"	"Detected in many"			"Region enhanced"	"Detected in many"		"midbrain: 6.9"	HPA016436	Enhanced									"HPA016436: AB_1847423"	"unprognostic (8.89e-2)"	"unprognostic (6.96e-2)"	"unprognostic (4.95e-3)"	"unprognostic (9.31e-2)"	"unprognostic (9.42e-4)"	"unprognostic (1.90e-1)"	"unprognostic (1.55e-3)"	"unprognostic (8.06e-2)"	"unprognostic (3.04e-1)"	"unprognostic (2.95e-1)"	"unprognostic (1.77e-2)"	"unprognostic (5.45e-2)"	"unprognostic (9.66e-4)"	"unprognostic (2.40e-2)"	"unprognostic (2.74e-1)"	"unprognostic (3.04e-2)"	"unprognostic (7.95e-2)"	0.4	145.3	0.4	0.1	14.8	0.0	0.4	0.3	0.3	0.2	0.2	7.6	0.1	0.0	0.3	0.5	1.5	0.3	0.0	0.3	0.3	0.2	0.1	0.7	0.1	0.0	0.3	0.2	9.2	0.1	0.0	0.4	157.2	0.2	0.2	0.0	0.3	0.1	0.6	0.3	0.1	0.1	0.3	0.3	5.7	0.1	20.4	0.1	0.0	0.1	0.3	0.7	0.2	0.2	0.0	0.0	15.8	0.0	0.4	0.1	0.1	0.0	0.0	0.0	0.2	0.0	0.3	43.1	0.1	0.0	0.3	0.1	0.0	0.0	0.0	1.0	0.1	0.0	0.0	0.0	0.2	0.0	0.1	34.2	1.0	0.3	0.2	0.0	0.2	1.5	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.1	0.0	0.1	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.2	8.7	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.2	0.0	0.1	0.0	0.0	0.1	0.0	0.0	15.8	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.1	0.4	14.8	0.3	0.3	0.3	0.2	0.3	0.2	0.2	0.1
CYP11B1	"CPN1, CYP11B, FHI, P450C11"	ENSG00000160882	"Cytochrome P450 family 11 subfamily B member 1"	P15538	8	142872356-142879846	"Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins"	"Lipid biosynthesis, Lipid metabolism, Steroid biosynthesis, Steroidogenesis"	"Monooxygenase, Oxidoreductase"	"Congenital adrenal hyperplasia, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in single"	781	"adrenal gland: 224.9"	"Group enriched"	"Detected in some"	8	"SCLC-21H: 3.0;SH-SY5Y: 1.2"	"Not detected"	"Not detected"							"Not detected"	"Not detected"			"Not detected"	"Not detected"											"HPA049171, HPA056348, HPA057752"	Supported									"HPA049171: , HPA056348: , HPA057752: "																		0.0	224.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0			0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		0.0	0.0	0.0	0.0	0.0		0.0	0.0		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1			0.0		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.0	1.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.2	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0										
CYP11B2	"ALDOS, CPN2, CYP11B, CYP11BL, P-450C18, P450aldo"	ENSG00000179142	"Cytochrome P450 family 11 subfamily B member 2"	P19099	8	142910559-142917843	"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins"	"Lipid metabolism, Steroid metabolism, Steroidogenesis"	"Monooxygenase, Oxidoreductase"	"Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in single"	259	"adrenal gland: 51.3"	"Not detected"	"Not detected"			"Not detected"	"Not detected"							"Not detected"	"Not detected"			"Not detected"	"Not detected"											"HPA049171, HPA056348, HPA057752"	Supported									"HPA049171: , HPA056348: , HPA057752: "																		0.0	51.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0			0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		0.0	0.0	0.0	0.0	0.0		0.0	0.0		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0			0.0		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0										
CYP17A1	"CPT7, CYP17, P450C17, S17AH"	ENSG00000148795	"Cytochrome P450 family 17 subfamily A member 1"	P05093	10	102830531-102837533	"Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"	Steroidogenesis	"Lyase, Monooxygenase, Oxidoreductase"	"Congenital adrenal hyperplasia, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	5	"adrenal gland: 425.4"	"Group enriched"	"Detected in some"	4	"HMC-1: 7.8;SCLC-21H: 3.1"	"Cancer enriched"	"Detected in many"	5	"liver cancer: 22.7"	"Region enriched"	"Detected in single"	103	"basal ganglia: 19.7"	"Cell type enhanced"	"Detected in single"		"neutrophil: 1.2"	"Lineage enhanced"	"Detected in single"		"granulocytes: 1.2"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			HPA048533	Enhanced				"Intracellular and membrane"					"HPA048533: "	"unprognostic (1.07e-2)"	"unprognostic (8.84e-2)"	"unprognostic (3.01e-2)"	"unprognostic (9.08e-2)"	"unprognostic (1.91e-1)"	"unprognostic (6.29e-2)"	"unprognostic (2.92e-3)"	"unprognostic (2.39e-4)"	"unprognostic (8.26e-2)"	"unprognostic (2.35e-1)"	"unprognostic (5.92e-3)"	"unprognostic (1.13e-1)"	"prognostic favourable (5.43e-7)"	"unprognostic (1.07e-1)"	"unprognostic (5.56e-2)"	"unprognostic (1.66e-2)"	"unprognostic (2.94e-4)"	0.0	425.4	0.0	0.1	19.7	0.0	0.0	0.1	0.1	0.1	0.0	78.5	0.0	0.0	0.1	0.3	0.1	0.1	0.0	0.1	0.0	0.0	6.4	1.7	0.1	0.0	0.0	0.0	3.2	0.1	0.2	0.0	0.0	0.1	0.0	0.0	0.2	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.1	0.1	82.3	0.0	0.1	2.2	0.0	0.0	0.1	0.0	0.0	0.0	1.2	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	7.8	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.1	0.1	3.1	1.3	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.2	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2	0.0	0.2	0.0	0.0	0.0	0.0	19.7	0.1	0.1	0.0	0.0	0.0	0.0	0.1	0.0
CYP21A2	"CA21H, CAH1, CPS1, CYP21, CYP21B, P450c21B"	ENSG00000231852	"Cytochrome P450 family 21 subfamily A member 2"	P08686	6	32038265-32041670	"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins"	Steroidogenesis	"Monooxygenase, Oxidoreductase"	"Congenital adrenal hyperplasia, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	23	"adrenal gland: 170.9"	"Cell line enhanced"	"Detected in some"		"HDLM-2: 11.5;Hep G2: 1.8;Karpas-707: 3.1"	"Cancer enhanced"	"Detected in some"		"liver cancer: 2.7"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"							"Low region specificity"	"Detected in many"			"HPA048979, HPA053371"	Enhanced				"Intracellular and membrane"					"HPA048979: AB_2680584, HPA053371: AB_2682131"	"unprognostic (1.03e-2)"	"unprognostic (1.65e-1)"	"unprognostic (1.02e-4)"	"unprognostic (2.58e-1)"	"unprognostic (2.97e-1)"	"unprognostic (2.93e-2)"	"unprognostic (2.76e-2)"	"unprognostic (8.75e-2)"	"unprognostic (1.39e-1)"	"unprognostic (1.71e-1)"	"unprognostic (1.41e-1)"	"unprognostic (1.93e-1)"	"unprognostic (6.67e-7)"	"unprognostic (7.39e-2)"	"unprognostic (5.24e-2)"	"unprognostic (1.09e-1)"	"unprognostic (1.82e-1)"	0.1	170.9	0.1	0.1	0.1	0.0	0.1	0.1	0.1	0.1	0.1	6.7	0.1	0.0	0.1	0.2	0.1	0.0	0.1	0.1	0.1	0.0	0.3	7.4	0.1	0.1	0.1	0.1	0.2	0.1	0.0	0.1	0.1	0.1	0.1	0.0	0.1	0.1	0.1	0.1	0.0	0.1	0.1	0.1	3.6	0.0	0.4	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	11.5	0.3	0.0	0.0	1.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.4	1.1	0.0	0.0	0.1	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.1	0.1	0.0	0.1	0.1	0.1	0.1
DBH	DBM	ENSG00000123454	"Dopamine beta-hydroxylase"	P09172	9	133636360-133659344	"Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"	"Catecholamine biosynthesis"	"Monooxygenase, Oxidoreductase"	"Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	9	"adrenal gland: 86.6;brain: 36.2;liver: 35.6"	"Cell line enriched"	"Detected in single"	340	"SH-SY5Y: 201.2"	"Low cancer specificity"	"Detected in some"			"Region enriched"	"Detected in single"	45	"pons and medulla: 36.2"	"Cell type enhanced"	"Detected in single"		"naive CD4 T-cell: 2.0"	"Lineage enriched"	"Detected in single"	21	"T-cells: 2.0"	"Region enriched"	"Detected in some"	6	"pons and medulla: 23.2"	"Region enriched"	"Detected in single"	37	"pons and medulla: 25.1"	"HPA002130, HPA005960, HPA070789"	Enhanced		Supported	"Endoplasmic reticulum,Vesicles"	"Intracellular and membrane"		2000000000	Vesicles	"Endoplasmic reticulum"	"HPA002130: AB_2666554, HPA005960: AB_1078628, HPA070789: AB_2686312"	"unprognostic (1.93e-3)"	"unprognostic (7.52e-3)"	"unprognostic (8.53e-2)"	"unprognostic (2.10e-2)"	"unprognostic (2.18e-3)"	"unprognostic (3.38e-3)"	"unprognostic (3.39e-3)"	"unprognostic (3.97e-2)"	"unprognostic (1.71e-1)"	"unprognostic (8.99e-2)"	"unprognostic (5.80e-2)"	"unprognostic (7.69e-2)"	"unprognostic (2.81e-7)"	"unprognostic (9.31e-2)"	"unprognostic (6.77e-2)"	"unprognostic (1.49e-2)"	"unprognostic (5.06e-3)"	0.7	86.6	0.1	0.3	0.1	0.0	0.0	0.1	0.8	0.3	0.0	1.9	0.7	0.1	0.1	0.0	0.0	0.1	0.1	0.1	0.0	0.1	0.5	35.6	0.3	0.6	0.0	0.0	0.1	1.3	0.0	0.6	0.4	36.2	0.8	0.0	1.0	0.2	5.9	0.0	0.0	0.2	0.0	1.4	0.4	0.1	0.0	0.0	0.1	0.1	0.0	0.0	0.8	0.5	0.0	0.0	0.0	0.0	0.0	2.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.1	0.0	0.0	0.0	0.5	0.5	0.0	0.0	0.2	201.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	2.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.8	0.0	0.1	0.0	0.0	36.2	0.0
DLK1	"Delta1, FA1, pG2, Pref-1, ZOG"	ENSG00000185559	"Delta like non-canonical Notch ligand 1"	P80370	14	100725705-100738224	"Predicted intracellular proteins, Predicted membrane proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	5	"adrenal gland: 157.6;pituitary gland: 143.1;placenta: 244.9"	"Group enriched"	"Detected in some"	6	"AF22: 22.5;Hep G2: 75.2;SH-SY5Y: 89.6"	"Cancer enhanced"	"Detected in many"		"liver cancer: 28.1"	"Group enriched"	"Detected in some"	5	"hypothalamus: 2.6;pons and medulla: 6.0"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Region enhanced"	"Detected in some"		"hypothalamus: 65.4"	"Region enhanced"	"Detected in many"		"midbrain: 159.6"	"CAB005872, HPA062262"	Enhanced		Approved	"Golgi apparatus"			160000	"Golgi apparatus"		"CAB005872: AB_731965, HPA062262: "	"unprognostic (2.16e-2)"			"prognostic unfavourable (2.31e-4)"	"unprognostic (1.49e-1)"	"unprognostic (1.14e-1)"	"unprognostic (4.89e-3)"	"unprognostic (5.75e-2)"		"unprognostic (1.87e-2)"	"unprognostic (1.12e-1)"	"unprognostic (5.24e-1)"		"unprognostic (3.11e-2)"	"unprognostic (6.57e-2)"			0.3	157.6	0.2	0.7	0.8	0.0	0.9	0.0	0.1	0.5	0.0	1.8	0.2	0.2	0.2	4.4	0.3	0.3	0.8	2.7	0.1	2.6	0.1	0.1	0.1	0.1	0.8	0.0	34.9	4.6	0.0	143.1	244.9	6.0	0.2	0.0	0.2	8.2	0.0	2.0	0.1	0.2	0.2	0.3	0.2	0.2	14.2	0.0	0.5	0.0	10.0	1.3	0.5	0.1	0.0	0.0	0.0	0.0	0.0	0.0	2.0	0.0	0.0	22.5	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	2.2	0.0	75.2	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	10.7	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.2	0.0	0.0	0.1	6.3	89.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	6.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.0	0.2	0.8	0.0	0.0	0.1	2.6	0.8	0.0	6.0	0.0
ELAVL4	"HUD, PNEM"	ENSG00000162374	"ELAV like RNA binding protein 4"	P26378	1	50048014-50203786	"Predicted intracellular proteins"	"mRNA processing, mRNA splicing"	RNA-binding		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 43.1"	"Cell line enriched"	"Detected in some"	19	"SH-SY5Y: 52.5"	"Group enriched"	"Detected in some"	10	"glioma: 2.6;pancreatic cancer: 0.6;testis cancer: 0.5"	"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"intermediate monocyte: 1.4;non-classical monocyte: 3.1"	"Lineage enriched"	"Detected in single"	5	"monocytes: 3.1"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB004442, HPA043047"	Enhanced		Approved	Nucleoplasm,Vesicles				"Nucleoplasm, Vesicles"		"CAB004442: AB_627765, HPA043047: "	"unprognostic (1.25e-1)"	"unprognostic (6.63e-3)"	"unprognostic (4.43e-2)"	"unprognostic (1.13e-1)"	"unprognostic (1.95e-1)"	"unprognostic (3.28e-2)"	"unprognostic (3.83e-4)"	"unprognostic (4.52e-2)"	"unprognostic (2.63e-1)"	"unprognostic (2.75e-1)"	"unprognostic (3.75e-3)"	"unprognostic (7.91e-2)"	"unprognostic (2.39e-3)"	"unprognostic (7.83e-2)"	"unprognostic (2.81e-2)"	"unprognostic (4.13e-2)"	"unprognostic (7.43e-2)"	0.9	11.4	11.5	3.3	12.8	0.8	1.0	11.6	43.1	0.9	3.0	0.9	0.0	2.3	0.9	0.8	1.1	0.9	1.0	1.0	12.3	16.5	0.9	1.0	1.0	0.9	10.6	30.7	0.8	2.8	0.8	7.1	0.9	37.0	1.0	3.8	0.0	0.9	0.9	0.8	1.2	3.1	2.0	8.5	1.0	1.9	7.8	1.4	0.1	0.8	0.0	1.0	0.9	0.5	0.0	0.6	0.0	3.1	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.7	0.0	0.0	0.0	0.0	0.0	52.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	1.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	3.1	0.6	0.0	0.0	11.5	12.8	11.6	40.4	12.3	16.5	10.6	30.7	37.0	1.4
ELOVL5	"dJ483K16.1, HELO1, SCA38"	ENSG00000012660	"ELOVL fatty acid elongase 5"	Q9NYP7	6	53267398-53349179	"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins"	"Fatty acid biosynthesis, Fatty acid metabolism, Lipid biosynthesis, Lipid metabolism"	Transferase	"Disease mutation, Neurodegeneration, Spinocerebellar ataxia"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB017042, HPA047752, HPA054197"	Enhanced		Enhanced	"Endoplasmic reticulum"				"Endoplasmic reticulum"		"CAB017042: , HPA047752: , HPA054197: "	"unprognostic (7.33e-2)"	"unprognostic (5.80e-2)"	"unprognostic (1.04e-1)"	"unprognostic (1.92e-2)"	"unprognostic (1.16e-1)"	"unprognostic (5.01e-2)"	"unprognostic (3.06e-1)"	"unprognostic (2.19e-1)"	"unprognostic (4.38e-2)"	"unprognostic (1.43e-2)"	"unprognostic (3.23e-1)"	"unprognostic (6.40e-2)"	"prognostic unfavourable (1.94e-6)"	"unprognostic (1.58e-1)"	"unprognostic (5.12e-2)"	"prognostic unfavourable (6.80e-4)"	"unprognostic (2.76e-2)"	75.7	48.7	17.9	24.2	22.0	33.9	78.8	13.3	22.1	18.2	13.9	38.3	91.2	9.7	15.7	18.0	10.8	16.5	18.0	14.6	18.3	17.5	13.5	36.8	24.4	33.6	41.1	12.3	13.1	5.7	8.1	11.6	13.6	26.4	45.2	6.7	16.1	9.4	88.4	3.6	11.4	17.3	18.0	46.4	18.5	9.5	34.8	29.1	28.7	17.6	5.6	33.6	16.6	19.4	23.8	18.1	60.7	11.3	8.4	25.3	10.4	25.5	18.7	32.8	59.9	87.1	50.6	14.0	29.9	33.6	24.2	34.0	16.5	29.7	29.1	21.7	31.0	15.2	32.3	27.3	36.3	24.5	22.7	28.7	17.4	23.0	47.9	22.6	21.0	46.7	21.5	24.2	30.4	26.8	35.8	16.9	17.4	2.8	67.2	20.1	17.7	14.3	26.2	22.5	10.1	45.5	15.3	30.6	21.1	24.7	12.9	25.0	29.5	21.2	25.4	26.6	23.6	47.3	39.3	14.3	13.1	22.1	13.8	33.0	18.8	9.0	11.3	40.7	8.8	8.1	14.2	21.6	14.7	10.6	18.1	23.8	7.2	6.7	60.7	8.4	9.6	4.8	25.3	10.4	17.9	22.0	13.3	20.2	18.3	17.5	41.1	12.3	26.4	29.1
ESR2	"ER-beta, Erb, NR3A2"	ENSG00000140009	"Estrogen receptor 2"	Q92731	14	64084232-64338112	"Cancer-related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, DNA-binding, Receptor"	"Cancer-related genes, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enhanced"	"Detected in many"		"ovary: 19.1;testis: 30.2;vagina: 14.3"	"Cell line enhanced"	"Detected in some"		"U-266/70: 10.5;U-698: 17.2"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in some"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in some"			"Region enriched"	"Detected in many"	5	"cerebellum: 17.8"	CAB079300	Enhanced									"CAB079300: "	"unprognostic (7.63e-3)"	"unprognostic (2.28e-3)"	"unprognostic (8.27e-3)"	"unprognostic (5.41e-2)"	"unprognostic (2.91e-2)"	"unprognostic (1.06e-1)"	"unprognostic (1.80e-1)"	"unprognostic (4.38e-2)"	"unprognostic (1.95e-1)"	"unprognostic (8.75e-2)"	"unprognostic (2.57e-2)"	"unprognostic (1.65e-1)"	"unprognostic (3.03e-5)"	"unprognostic (1.57e-1)"	"unprognostic (1.66e-1)"	"unprognostic (4.21e-2)"	"unprognostic (5.89e-2)"	2.1	9.4	0.2	2.3	0.8	1.0	3.7	0.8	0.6	1.3	2.9	0.6	0.2	1.4	1.7	0.7	1.7	1.1	0.6	1.0	1.1	0.4	1.4	0.7	1.3	2.8	0.2	0.2	19.1	2.5	0.0	1.6	0.7	1.4	2.2	1.5	0.5	1.5	0.9	1.4	1.2	1.5	0.6	1.0	3.0	1.3	30.2	0.6	5.0	0.6	0.2	2.9	1.8	14.3	2.4	4.0	1.1	0.3	0.4	1.3	0.2	0.7	0.3	0.7	0.6	0.0	0.1	1.3	0.1	0.0	0.1	0.1	0.2	0.8	2.8	0.1	0.0	1.0	0.9	0.0	0.1	0.7	0.3	0.3	0.7	0.1	0.1	0.1	0.2	0.0	0.0	0.1	0.2	0.2	0.6	4.0	0.1	0.7	0.4	0.2	0.7	0.4	0.5	0.3	0.2	0.1	1.3	2.4	0.7	0.5	0.2	1.1	0.8	0.0	0.4	0.5	0.9	0.2	0.1	10.5	3.2	17.2	0.2	0.1	0.7	0.3	0.3	1.0	0.8	0.2	0.6	1.7	0.6	1.1	0.1	2.4	1.3	1.0	1.1	0.4	0.2	4.0	0.5	0.2	0.2	0.8	0.8	0.6	1.1	0.4	0.2	0.2	1.4	0.6
FDX1	"ADX, FDX"	ENSG00000137714	"Ferredoxin 1"	P10109	11	110429883-110464881	"Predicted intracellular proteins"	"Cholesterol metabolism, Electron transport, Lipid metabolism, Steroid metabolism, Steroidogenesis, Sterol metabolism, Transport"			"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"adrenal gland: 113.9;seminal vesicle: 55.6"	"Cell line enhanced"	"Detected in all"		"U-698: 37.2"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA041630, HPA062087"	Enhanced		Enhanced	Mitochondria				Mitochondria		"HPA041630: AB_10793970, HPA062087: AB_2630366"	"unprognostic (1.66e-1)"	"unprognostic (1.68e-2)"	"unprognostic (5.29e-3)"	"unprognostic (4.67e-2)"	"unprognostic (2.39e-1)"	"unprognostic (4.32e-3)"	"unprognostic (1.23e-2)"	"unprognostic (2.07e-1)"	"unprognostic (2.19e-2)"	"unprognostic (4.12e-1)"	"unprognostic (3.10e-2)"	"unprognostic (5.48e-2)"	"prognostic favourable (3.58e-7)"	"prognostic favourable (2.53e-4)"	"unprognostic (1.10e-1)"	"unprognostic (1.94e-1)"	"unprognostic (2.80e-1)"	5.5	113.9	3.9	4.7	4.5	3.9	5.6	2.7	4.0	3.2	7.5	5.2	33.7	7.9	3.2	3.9	5.1	3.0	5.6	9.6	3.6	4.3	10.7	22.8	7.8	4.7	4.5	2.5	3.5	8.6	3.5	3.7	48.4	3.1	4.8	4.2	4.2	4.1	55.6	7.3	3.3	12.3	3.6	3.4	3.9	5.0	5.3	2.6	5.2	8.7	5.0	3.5	5.6	5.4	10.7	6.9	3.4	5.8	4.4	8.7	2.9	5.2	3.7	5.7	6.2	5.6	10.0	12.8	4.9	6.0	4.3	7.4	12.6	8.9	12.4	14.4	6.3	6.3	6.6	7.4	5.9	11.8	8.4	6.2	6.5	7.7	9.8	6.5	10.2	17.3	6.1	3.9	9.3	8.8	6.2	18.5	9.2	5.8	9.2	14.6	5.1	7.0	13.7	5.4	11.4	9.4	9.5	7.8	4.0	9.3	10.6	6.2	6.2	4.5	5.2	4.4	5.4	5.3	5.2	4.2	3.2	37.2	3.3	13.4	5.6	1.8	5.7	3.4	5.3	4.2	5.8	10.7	7.3	7.4	6.9	7.5	8.6	6.1	0.7	4.4	5.8	5.3	8.7	2.9	3.9	4.5	2.7	4.0	3.6	4.3	4.5	2.5	3.1	2.6
FDXR	ADXR	ENSG00000161513	"Ferredoxin reductase"	P22570	17	74862497-74873031	"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins"	"Cholesterol metabolism, Electron transport, Lipid metabolism, Steroid metabolism, Sterol metabolism, Transport"	Oxidoreductase	"Deafness, Disease mutation, Neuropathy"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"adrenal gland: 93.9"	"Cell line enhanced"	"Detected in many"		"BEWO: 29.5;Hep G2: 54.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB008597, CAB009818, HPA044393, HPA053673"	Enhanced		Enhanced	Mitochondria				Mitochondria		"CAB008597: AB_1615557, CAB009818: AB_2102601, HPA044393: AB_2678927, HPA053673: AB_2682225"	"unprognostic (2.69e-2)"	"unprognostic (1.17e-3)"	"unprognostic (7.51e-2)"	"prognostic favourable (2.38e-4)"	"unprognostic (3.43e-2)"	"unprognostic (1.20e-1)"	"unprognostic (1.53e-1)"	"unprognostic (1.68e-2)"	"unprognostic (2.29e-1)"	"unprognostic (1.50e-1)"	"unprognostic (1.09e-1)"	"unprognostic (6.30e-2)"	"unprognostic (1.42e-2)"	"unprognostic (1.19e-2)"	"unprognostic (4.50e-2)"	"unprognostic (4.03e-2)"	"unprognostic (2.13e-1)"	1.7	93.9	2.6	2.1	3.1	1.3	1.8	8.4	2.7	2.1	4.6	3.2	6.4	2.6	2.6	23.8	8.7	6.6	6.1	1.9	3.4	1.7	2.7	4.1	4.4	1.7	2.9	3.5	7.1	3.9	2.3	1.5	2.6	3.6	3.3	2.1	0.9	5.3	4.2	7.9	5.6	2.5	2.0	4.4	9.7	2.2	32.1	3.0	3.9	2.0	7.7	3.7	3.0	3.0	5.4	7.4	4.8	6.4	10.0	15.2	5.6	3.9	21.1	3.1	3.5	2.3	3.0	29.5	4.7	5.2	2.8	5.7	5.9	3.5	9.4	0.8	2.0	8.1	2.3	5.9	0.8	8.9	4.9	7.1	3.5	54.0	6.4	1.5	25.0	9.9	6.7	2.9	1.0	14.4	11.3	1.5	4.3	16.7	6.1	3.3	1.7	4.6	3.3	5.3	5.0	2.3	6.7	1.7	4.0	3.2	7.1	3.4	15.4	1.5	6.7	1.9	17.6	3.1	2.3	4.4	0.7	2.0	5.3	2.4	6.6	1.8	6.4	4.8	6.2	4.3	5.3	5.4	5.6	7.3	7.4	2.8	4.9	6.1	2.1	10.0	3.2	1.4	15.2	5.6	2.6	3.1	8.4	2.7	3.4	1.7	2.9	3.5	3.6	3.0
FGF11	"FHF3, FLJ16061, MGC102953, MGC45269"	ENSG00000161958	"Fibroblast growth factor 11"	Q92914	17	7438273-7444937	"Predicted intracellular proteins"		"Growth factor"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at transcript level"		"Tissue enhanced"	"Detected in many"		"adrenal gland: 23.5"	"Cell line enhanced"	"Detected in many"		"A-431: 9.3;HaCaT: 16.9;LHCN-M2: 11.2"	"Low cancer specificity"	"Detected in some"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in single"		"eosinophil: 1.6"	"Low lineage specificity"	"Detected in single"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA066605, HPA075188"	Enhanced		Approved	Centrosome				Centrosome		"HPA066605: , HPA075188: "	"unprognostic (7.35e-2)"	"unprognostic (1.14e-2)"	"unprognostic (7.67e-3)"	"unprognostic (2.79e-4)"	"unprognostic (9.15e-2)"	"unprognostic (3.28e-2)"	"unprognostic (7.31e-2)"	"unprognostic (3.11e-2)"	"unprognostic (1.59e-2)"	"unprognostic (1.45e-1)"	"unprognostic (4.69e-2)"	"unprognostic (2.89e-3)"	"unprognostic (2.00e-6)"	"unprognostic (1.12e-1)"	"unprognostic (2.30e-1)"	"unprognostic (6.90e-3)"	"unprognostic (4.97e-3)"	3.3	23.5	10.5	3.0	13.8	2.1	2.9	4.5	11.6	6.4	1.6	4.6	0.1	1.8	3.1	1.9	13.0	1.7	3.2	11.6	11.7	4.6	3.4	1.1	1.3	6.2	8.1	5.2	1.6	1.3	1.5	1.0	2.0	10.6	1.4	1.4	6.8	3.7	1.7	8.8	19.7	1.3	2.9	4.1	2.4	1.6	2.8	9.9	2.5	7.2	7.1	9.0	2.9	8.7	0.0	0.0	1.6	0.6	0.0	0.3	0.0	9.3	0.6	5.2	0.0	3.0	0.1	2.6	0.2	3.2	0.3	0.6	0.2	1.0	2.8	0.7	0.1	16.9	1.9	5.3	1.2	5.8	4.1	5.1	0.5	1.3	0.5	0.2	5.7	0.6	1.5	0.4	0.2	0.2	2.0	0.2	11.2	2.1	1.6	2.2	1.9	0.2	4.4	4.7	1.1	0.7	0.8	1.1	5.3	0.6	0.6	0.4	0.3	0.4	0.1	0.3	5.6	0.0	0.2	0.4	1.3	0.9	1.3	3.1	0.6	0.0	0.0	1.6	0.1	0.1	0.0	0.0	0.0	0.2	0.0	0.0	0.2	0.0	0.0	0.0	0.6	0.0	0.3	0.0	10.5	13.8	4.5	11.6	11.7	4.6	8.1	5.2	10.6	9.9
HCN4		ENSG00000138622	"Hyperpolarization activated cyclic nucleotide gated potassium channel 4"	Q9Y3Q4	15	73319859-73369264	"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels"	"Ion transport, Potassium transport, Sodium transport, Transport"	"Ion channel, Ligand-gated ion channel, Potassium channel, Sodium channel, Voltage-gated channel"	"Brugada syndrome, Disease mutation"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	4	"brain: 4.3;heart muscle: 12.5;testis: 9.6"	"Cell line enhanced"	"Detected in some"		"AF22: 2.5;CACO-2: 3.1;HDLM-2: 2.1;NTERA-2: 9.4;U-2 OS: 4.1"	"Group enriched"	"Detected in some"	8	"testis cancer: 3.1;thyroid cancer: 0.7"	"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			HPA073174	Approved									"HPA073174: "	"unprognostic (2.21e-1)"	"unprognostic (1.39e-1)"	"unprognostic (2.18e-2)"	"unprognostic (3.14e-2)"	"unprognostic (5.30e-3)"	"unprognostic (1.92e-2)"	"unprognostic (2.19e-1)"	"unprognostic (3.50e-2)"	"unprognostic (2.37e-1)"	"unprognostic (6.56e-2)"	"unprognostic (1.13e-3)"	"unprognostic (1.13e-1)"	"unprognostic (6.05e-5)"	"unprognostic (5.56e-2)"	"unprognostic (4.60e-2)"	"unprognostic (1.51e-2)"	"unprognostic (7.95e-2)"	0.2	1.3	4.3	0.2	1.1	0.1	0.1	0.9	3.4	0.2	0.4	2.1	0.0	1.2	0.1	0.2	0.1	0.3	0.2	12.5	0.6	2.0	0.4	0.1	0.3	0.1	1.8	0.9	0.1	0.2	0.1	2.1	0.1	3.9	0.6	0.3	0.2	0.1	1.0	0.1	0.2	0.4	0.2	0.7	0.1	0.6	9.6	1.9	0.0	0.3	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	2.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.1	0.2	0.0	1.5	0.0	0.2	0.0	0.0	0.1	2.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	9.4	0.0	0.0	0.0	0.0	0.3	0.0	1.1	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	4.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.3	1.1	0.9	3.4	0.6	2.0	1.8	0.9	3.9	1.9
HSD3B1	"HSD3B, HSDB3, SDR11E1"	ENSG00000203857	"Hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1"	P14060	1	119507198-119515054	"Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"	"Lipid metabolism, Steroid metabolism, Steroidogenesis"	"Isomerase, Multifunctional enzyme, Oxidoreductase"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	19	"placenta: 231.4"	"Cell line enriched"	"Detected in some"	9	"CACO-2: 37.0"	"Cancer enhanced"	"Detected in single"		"urothelial cancer: 1.6"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"											"HPA043261, HPA043264, HPA044028"	Supported		Approved	"Nucleoli,Endoplasmic reticulum,Cytokinetic bridge"				"Nucleoli, Endoplasmic reticulum"	"Cytokinetic bridge"	"HPA043261: , HPA043264: , HPA044028: "			"unprognostic (1.53e-1)"				"unprognostic (7.11e-2)"					"unprognostic (1.15e-1)"		"unprognostic (1.04e-1)"			"prognostic favourable (4.59e-5)"	0.1	0.6	0.0	0.0	0.3	0.0	0.7	0.0	0.1	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.6	0.1	0.0	0.0	0.0	0.1	0.5	0.0	0.0	231.4	0.1	0.0	0.1	0.0	0.0	0.0	0.0	4.5	11.9	0.2	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.6	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.1	0.0	0.0	0.0	37.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	2.2	0.0	0.0	4.1	0.4	0.5	0.0	0.0	0.1	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.3	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0
HSD3B2	SDR11E2	ENSG00000203859	"Hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2"	P26439	1	119414931-119423035	"Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"	Steroidogenesis	"Isomerase, Multifunctional enzyme, Oxidoreductase"	"Congenital adrenal hyperplasia, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	5	"adrenal gland: 223.2"	"Cell line enhanced"	"Detected in some"		"SCLC-21H: 1.5;SH-SY5Y: 1.4;SK-MEL-30: 5.1;TIME: 1.2;WM-115: 3.2"	"Cancer enhanced"	"Detected in single"		"testis cancer: 0.6"	"Region enriched"	"Detected in single"	198	"basal ganglia: 19.8"	"Not detected"	"Not detected"			"Not detected"	"Not detected"											"HPA043261, HPA043264, HPA044028"	Supported		Uncertain	"Nucleoli,Endoplasmic reticulum,Cytokinetic bridge"				"Nucleoli, Endoplasmic reticulum"	"Cytokinetic bridge"	"HPA043261: , HPA043264: , HPA044028: "	"unprognostic (3.56e-1)"		"unprognostic (1.85e-1)"		"unprognostic (2.80e-1)"		"unprognostic (2.72e-2)"		"unprognostic (8.87e-2)"	"unprognostic (3.91e-2)"	"unprognostic (3.43e-2)"	"unprognostic (1.94e-1)"	"unprognostic (6.51e-2)"	"unprognostic (1.97e-2)"	"unprognostic (1.55e-1)"			0.0	223.2	0.0	0.8	19.8	0.0	0.0	0.0	0.0	0.0	0.5	43.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.4	0.0	0.0	0.0	0.9	0.0	0.0	0.1	0.3	0.0	0.0	0.0	0.0	3.6	0.2	0.0	0.0	0.0	1.9	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.3	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.6	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.3	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.9	0.0	0.0	0.1	0.0	0.0	0.0	1.5	1.4	0.0	0.0	5.1	0.0	0.0	1.2	0.2	0.1	0.1	0.7	0.0	0.0	0.0	0.8	0.0	3.2	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	19.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
HTR4	5-HT4	ENSG00000164270	"5-hydroxytryptamine receptor 4"	Q13639	5	148451032-148677235	"FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins"		"G-protein coupled receptor, Receptor, Transducer"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"		"Group enriched"	"Detected in some"	7	"brain: 18.1;heart muscle: 7.2;intestine: 14.6;pituitary gland: 5.9"	"Cell line enriched"	"Detected in single"	5	"Karpas-707: 2.6"	"Not detected"	"Not detected"			"Region enhanced"	"Detected in many"		"basal ganglia: 18.1"	"Cell type enriched"	"Detected in single"	8	"T-reg: 1.5"	"Lineage enriched"	"Detected in single"	15	"T-cells: 1.5"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			HPA040591	Enhanced									"HPA040591: "	"unprognostic (1.12e-1)"	"unprognostic (4.60e-2)"	"unprognostic (7.74e-2)"		"unprognostic (2.37e-1)"	"unprognostic (5.02e-2)"	"unprognostic (3.77e-2)"	"unprognostic (4.68e-2)"			"unprognostic (1.10e-2)"	"unprognostic (1.13e-1)"	"unprognostic (1.46e-1)"	"unprognostic (3.40e-2)"	"unprognostic (2.25e-1)"	"unprognostic (4.49e-2)"	"unprognostic (8.83e-5)"	0.4	1.4	1.9	1.1	18.1	0.1	0.2	0.1	3.2	0.6	4.3	0.0	0.0	8.0	0.3	0.1	0.3	0.4	1.5	7.2	5.2	0.6	0.1	0.2	0.3	0.2	0.5	1.3	0.2	0.1	0.1	5.9	0.1	0.1	0.1	4.9	0.0	0.2	0.2	0.2	0.2	14.6	1.1	0.3	0.2	0.2	0.2	2.4	0.0	0.2	0.0	0.1	0.1	0.2	0.0	0.0	0.0	0.0	0.0	1.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	2.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	1.5	0.0	1.9	18.1	0.1	3.2	5.2	0.6	0.5	1.3	0.1	2.4
MC2R	ACTHR	ENSG00000185231	"Melanocortin 2 receptor"	Q01718	18	13882044-13915707	"Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters"		"G-protein coupled receptor, Receptor, Transducer"	"Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"		"Group enriched"	"Detected in some"	8	"adrenal gland: 31.7;pituitary gland: 14.3"	"Cell line enhanced"	"Detected in some"		"HeLa: 1.8;MCF7: 3.7"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell type enhanced"	"Detected in single"		"basophil: 1.3"	"Lineage enriched"	"Detected in single"	4	"granulocytes: 1.3"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			HPA079148	Enhanced									"HPA079148: "											"unprognostic (2.09e-1)"			"unprognostic (3.63e-2)"	"unprognostic (1.85e-2)"			0.0	31.7	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	2.0	0.0	0.0	0.0	2.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	14.3	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.2	0.1	0.0	0.0	0.3	0.0	0.1	0.1	1.3	0.3	0.1	0.1	0.0	0.2	0.0	0.1	0.3	0.1	0.3	1.1	0.2	0.0	0.1	0.3	0.1	0.2	0.0	0.0	0.4	0.3	0.1	0.9	0.1	0.0	0.5	0.0	1.8	0.2	0.0	0.2	0.0	0.0	0.9	0.0	0.6	0.0	0.1	0.4	0.0	3.7	0.0	0.0	0.6	0.1	0.2	0.5	0.0	0.3	0.1	0.1	0.0	0.0	0.0	0.1	0.1	0.3	0.0	0.2	0.3	0.5	0.0	0.2	0.2	0.0	0.1	0.4	0.0	1.3	0.1	0.0	0.1	0.3	0.1	0.0	0.1	0.1	0.0	0.1	0.1	0.0	0.5	0.1	0.2	0.1	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0
MGARP	"C4orf49, CESP-1, HUMMR, OSAP"	ENSG00000137463	"Mitochondria localized glutamic acid rich protein"	Q8TDB4	4	139266163-139280338	"Predicted membrane proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"adrenal gland: 88.9;retina: 30.7"	"Cell line enhanced"	"Detected in some"		"BJ: 10.5;fHDF/TERT166: 15.6;HHSteC: 12.7;HUVEC TERT2: 31.7"	"Cancer enhanced"	"Detected in some"		"renal cancer: 4.1"	"Group enriched"	"Detected in many"	4	"basal ganglia: 4.5;cerebellum: 8.0"	"Cell type enhanced"	"Detected in some"		"memory CD4 T-cell: 1.7;naive CD4 T-cell: 1.6"	"Low lineage specificity"	"Detected in single"							"Low region specificity"	"Detected in single"			HPA015994	Enhanced		Supported	Mitochondria				Mitochondria		"HPA015994: "	"unprognostic (2.68e-1)"	"unprognostic (1.73e-1)"	"unprognostic (8.18e-2)"	"unprognostic (4.25e-2)"	"unprognostic (3.54e-2)"	"unprognostic (3.11e-2)"	"unprognostic (3.42e-2)"	"unprognostic (1.02e-3)"	"unprognostic (2.90e-2)"	"unprognostic (4.96e-2)"	"unprognostic (1.50e-2)"	"unprognostic (1.31e-1)"	"unprognostic (4.08e-2)"	"unprognostic (1.47e-2)"	"unprognostic (9.91e-2)"	"unprognostic (2.09e-2)"	"unprognostic (2.36e-1)"	3.2	88.9	1.0	0.5	4.5	0.4	1.2	8.0	1.2	3.6	1.0	2.1	1.1	0.4	2.6	3.0	0.5	0.8	1.3	6.1	0.8	1.4	1.0	0.4	0.5	0.6	1.0	0.0	20.1	0.5	0.4	15.3	0.5	1.5	2.0	0.5	30.7	0.4	2.0	0.6	0.5	0.4	2.3	0.7	0.6	0.4	5.9	0.5	0.0	0.5	0.0	0.5	2.1	1.0	0.5	0.0	0.0	0.3	0.5	1.7	0.3	0.0	0.5	0.3	0.2	0.8	0.4	0.0	10.5	0.0	1.5	0.0	0.0	0.1	0.0	0.1	15.6	0.2	2.2	0.0	0.9	0.0	1.0	0.0	0.0	0.1	12.7	0.1	0.1	3.8	0.3	1.7	0.1	31.7	0.2	0.2	2.6	0.0	0.4	0.2	0.6	0.0	0.0	0.0	0.0	0.3	0.1	0.3	0.6	0.0	0.0	0.1	0.0	0.2	0.3	0.0	0.0	0.0	0.0	0.4	0.3	0.2	4.4	0.4	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.5	1.7	0.4	0.0	0.3	1.6	0.7	0.0	0.5	0.2	0.0	0.3	0.3	1.0	4.5	8.0	1.2	0.8	1.4	1.0	0.0	1.5	0.5
NOV	"CCN3, IGFBP9"	ENSG00000136999	"Nephroblastoma overexpressed"	P48745	8	119416306-119424353	"Plasma proteins, Predicted secreted proteins, Transporters"		"Growth factor"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	8	"adrenal gland: 236.7"	"Group enriched"	"Detected in many"	5	"BJ hTERT+: 43.0;U-2197: 44.5"	"Cancer enhanced"	"Detected in all"		"melanoma: 62.7"	"Low region specificity"	"Detected in many"			"Group enriched"	"Detected in some"	113	"eosinophil: 28.1;neutrophil: 14.0"	"Lineage enriched"	"Detected in single"	151	"granulocytes: 28.1"	"Group enriched"	"Detected in many"	7	"amygdala: 134.6;basal ganglia: 51.6;cerebral cortex: 101.0;hippocampal formation: 166.1"	"Low region specificity"	"Detected in many"			"HPA018449, HPA019684, CAB034423"	Enhanced		Enhanced	Vesicles	"Secreted to blood"	269030000	2900000	Vesicles		"CAB034423: AB_2151387, HPA018449: AB_1846189, HPA019684: AB_1846190"	"unprognostic (5.04e-2)"	"unprognostic (1.01e-1)"	"unprognostic (7.36e-3)"	"unprognostic (1.30e-3)"	"unprognostic (9.35e-3)"	"unprognostic (4.92e-1)"	"unprognostic (8.10e-2)"	"unprognostic (6.04e-2)"	"unprognostic (1.79e-2)"	"unprognostic (9.17e-2)"	"unprognostic (1.67e-1)"	"unprognostic (3.10e-1)"	"unprognostic (2.66e-1)"	"unprognostic (8.74e-3)"	"unprognostic (1.51e-1)"	"unprognostic (1.98e-1)"	"unprognostic (2.72e-2)"	6.3	236.7	2.2	1.4	7.9	1.0	5.6	3.1	12.3	5.0	2.0	3.6	3.6	1.5	5.8	2.9	1.9	3.0	2.0	5.7	3.5	1.9	4.9	0.9	2.9	1.1	2.1	15.1	1.8	2.7	2.1	13.4	0.8	7.4	5.6	2.2	1.2	1.2	5.0	1.6	3.6	1.5	2.5	2.5	1.0	1.6	2.6	0.0	0.0	6.9	4.8	1.1	3.3	2.5	0.0	0.1	28.1	0.1	0.0	0.0	0.0	0.0	1.0	0.6	0.0	3.9	1.0	0.0	5.7	43.0	5.2	3.0	0.0	0.1	0.0	4.5	7.2	3.6	0.2	0.0	1.7	0.0	0.1	0.0	3.3	0.0	0.1	0.0	0.0	0.2	0.0	2.0	0.2	0.1	0.0	0.0	0.2	0.2	0.0	0.0	0.0	8.6	0.0	0.0	0.0	5.5	0.0	1.3	0.0	2.1	0.0	8.0	0.0	0.0	0.0	3.7	5.7	44.5	1.1	0.0	0.0	0.0	5.9	1.8	4.3	0.0	0.1	28.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	14.0	0.0	0.0	0.0	0.0	0.0	2.2	7.9	3.1	12.3	3.5	1.9	2.1	15.1	7.4	0.0
NPTX2		ENSG00000106236	"Neuronal pentraxin 2"	P47972	7	98617297-98629868	"Predicted secreted proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	4	"adrenal gland: 24.0;brain: 45.6;pancreas: 19.5;pituitary gland: 71.6;testis: 20.7"	"Cell line enriched"	"Detected in some"	12	"LHCN-M2: 125.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Cell type enriched"	"Detected in single"	16	"plasmacytoid DC: 1.5"	"Lineage enriched"	"Detected in single"	16	"dendritic cells: 1.5"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"CAB020801, HPA049799, HPA058320"	Enhanced		Approved	"Golgi apparatus,Actin filaments,Centrosome"	"Secreted to blood"	2488000	320000	"Golgi apparatus, Actin filaments"	Centrosome	"CAB020801: , HPA049799: , HPA058320: "	"unprognostic (1.18e-1)"	"unprognostic (9.61e-2)"	"unprognostic (1.56e-2)"	"prognostic unfavourable (5.46e-5)"	"unprognostic (1.91e-3)"	"unprognostic (9.20e-2)"	"unprognostic (2.42e-2)"	"unprognostic (6.04e-3)"	"unprognostic (1.11e-1)"	"unprognostic (1.74e-1)"	"unprognostic (7.64e-2)"	"unprognostic (2.35e-1)"	"prognostic unfavourable (5.46e-9)"	"unprognostic (1.06e-2)"	"unprognostic (1.21e-1)"	"unprognostic (5.33e-2)"	"unprognostic (3.69e-2)"	4.3	24.0	7.1	2.3	8.4	1.0	1.4	0.2	45.6	8.2	3.8	3.2	0.1	1.1	1.8	3.9	2.2	1.5	1.6	3.2	9.2	11.0	0.9	0.9	0.8	0.7	9.4	2.2	1.5	19.5	0.8	71.6	0.8	7.0	2.1	1.4	1.3	1.5	2.2	2.9	4.0	1.3	2.9	2.9	6.1	1.9	20.7	5.0	0.0	1.6	0.1	0.9	1.4	2.1	0.0	1.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.0	0.0	0.0	0.0	1.5	0.0	0.0	0.0	0.0	0.0	0.0	3.7	0.4	0.0	0.1	0.0	0.0	0.0	1.2	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.0	0.0	0.0	0.0	0.0	0.0	125.7	0.0	0.9	0.0	6.1	0.0	0.0	0.0	0.0	0.0	0.0	10.8	6.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.5	0.0	0.0	7.1	8.4	0.2	24.6	9.2	11.0	9.4	2.2	7.0	5.0
NRIP3	C11orf14	ENSG00000175352	"Nuclear receptor interacting protein 3"	Q9NQ35	11	8980576-9004049	"Predicted intracellular proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	4	"adrenal gland: 11.5;blood: 13.8;bone marrow: 12.7;brain: 28.4;testis: 30.3"	"Cell line enhanced"	"Detected in many"		"HMC-1: 25.8;SiHa: 16.7;U-87 MG: 24.1"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Cell type enriched"	"Detected in some"	7	"basophil: 13.8"	"Lineage enriched"	"Detected in many"	13	"granulocytes: 13.8"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA058827, HPA072961"	Approved		Approved	Cytosol				Cytosol		"HPA058827: , HPA072961: "	"unprognostic (2.05e-1)"	"unprognostic (1.42e-1)"	"unprognostic (8.84e-3)"	"unprognostic (5.43e-3)"	"unprognostic (1.66e-1)"	"unprognostic (2.68e-1)"	"unprognostic (2.03e-4)"	"unprognostic (1.25e-1)"	"unprognostic (1.88e-1)"	"unprognostic (3.63e-2)"	"unprognostic (1.04e-2)"	"unprognostic (1.11e-1)"	"unprognostic (1.33e-1)"	"unprognostic (1.13e-1)"	"unprognostic (1.41e-1)"	"unprognostic (5.88e-3)"	"unprognostic (1.30e-1)"	2.9	11.5	10.0	2.0	19.7	12.7	4.8	27.6	24.7	1.9	1.0	3.1	0.0	1.0	3.9	3.8	1.4	2.1	2.2	1.4	28.4	9.6	1.2	0.7	1.3	1.3	10.5	6.8	0.8	0.8	2.4	0.7	1.3	11.0	1.2	1.2	3.3	1.1	1.4	0.6	0.9	1.0	2.8	4.5	1.0	1.6	30.3	0.8	0.0	1.4	0.0	1.1	1.0	0.3	0.1	0.2	13.8	0.3	0.1	1.0	0.2	0.0	0.4	0.9	0.1	0.3	1.4	0.0	10.0	3.9	8.1	8.5	1.5	0.8	0.0	1.5	2.9	0.1	2.7	0.2	14.1	0.7	4.0	1.0	0.5	0.1	0.6	12.5	25.8	1.8	0.1	8.3	0.1	6.5	1.9	0.1	7.4	0.0	0.6	4.0	3.2	0.0	0.0	1.4	0.0	0.1	0.6	2.7	0.8	16.7	0.4	2.5	1.7	1.2	8.1	12.4	5.9	0.7	0.0	0.0	0.0	0.0	24.1	1.5	6.0	13.8	0.1	2.0	0.1	0.3	0.2	0.1	0.5	0.1	0.2	0.1	0.1	0.1	0.2	0.1	0.1	0.0	1.0	0.2	10.0	19.7	27.6	19.6	28.4	9.6	10.5	6.8	11.0	0.8
PCSK1N	"BigLEN, PEN, proSAAS, SAAS, SCG8, SgVIII"	ENSG00000102109	"Proprotein convertase subtilisin/kexin type 1 inhibitor"	Q9UHG2	X	48831094-48835633	"Predicted secreted proteins"		Neuropeptide		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 74.9;kidney: 72.9;pituitary gland: 127.7"	"Cell line enhanced"	"Detected in some"		"HEK 293: 19.6;PC-3: 49.6;SCLC-21H: 19.7;SH-SY5Y: 18.2;SiHa: 17.2;U-266/84: 22.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in many"	4	"MAIT T-cell: 3.0;memory CD4 T-cell: 6.5;memory CD8 T-cell: 6.3;naive CD4 T-cell: 2.7;naive CD8 T-cell: 8.2;T-reg: 2.1"	"Lineage enriched"	"Detected in single"	77	"T-cells: 8.2"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA003925, HPA064734"	Enhanced	Supported	Approved	Vesicles	"Secreted to blood"		5300000	Vesicles		"HPA003925: AB_1079582, HPA064734: AB_2685339"	"unprognostic (2.44e-3)"	"unprognostic (5.86e-2)"	"unprognostic (1.94e-1)"	"prognostic unfavourable (1.15e-4)"	"unprognostic (3.36e-1)"	"unprognostic (4.76e-3)"	"unprognostic (1.49e-2)"	"unprognostic (3.34e-1)"	"unprognostic (5.63e-2)"	"unprognostic (3.55e-1)"	"unprognostic (1.50e-3)"	"unprognostic (2.79e-3)"	"prognostic favourable (1.36e-4)"	"unprognostic (3.34e-2)"	"unprognostic (2.91e-2)"	"unprognostic (1.91e-1)"	"unprognostic (2.14e-1)"	4.1	27.5	49.1	2.6	72.7	2.1	2.2	15.6	70.3	3.2	9.8	10.8	1.5	12.4	4.4	10.9	2.1	2.3	2.8	2.7	38.5	74.9	72.9	2.1	2.6	2.2	33.5	29.0	2.2	20.0	12.4	127.7	2.3	32.9	4.6	2.7	6.6	2.8	3.1	2.2	2.8	8.5	2.7	18.3	2.4	26.0	3.8	9.8	0.0	2.2	0.0	2.1	2.1	0.5	0.1	0.0	0.0	0.0	0.0	8.2	0.8	0.0	1.8	0.0	5.0	0.2	0.0	0.1	0.0	0.0	0.0	0.0	1.7	0.0	0.0	3.5	0.0	0.2	0.0	0.3	0.0	0.0	19.6	0.0	0.0	2.9	0.0	0.0	1.2	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	2.4	0.0	0.1	2.7	49.6	0.0	0.0	0.1	0.4	0.0	19.7	18.2	17.2	0.0	1.4	0.0	0.0	0.0	0.0	7.6	0.0	1.6	4.5	22.9	0.0	0.1	0.0	0.5	0.0	0.0	0.0	1.1	0.0	3.0	0.0	6.5	6.3	0.0	0.1	2.7	8.2	0.0	0.0	0.0	0.0	2.1	0.8	49.1	72.7	15.6	70.3	38.5	74.9	33.5	29.0	32.9	9.8
PCSK2	"NEC2, PC2, SPC2"	ENSG00000125851	"Proprotein convertase subtilisin/kexin type 2"	P16519	20	17226107-17484578	"Enzymes, Predicted intracellular proteins, Predicted secreted proteins"		"Hydrolase, Protease, Serine protease"		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"adrenal gland: 35.0;thyroid gland: 79.5"	"Group enriched"	"Detected in some"	5	"AF22: 35.8;SCLC-21H: 9.4"	"Group enriched"	"Detected in many"	6	"pancreatic cancer: 14.6;thyroid cancer: 65.1"	"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in single"	22	"basophil: 2.2"	"Lineage enriched"	"Detected in single"	22	"granulocytes: 2.2"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA049627	Approved		Approved	Vesicles	"Secreted in other tissues"			Vesicles		"HPA049627: "	"unprognostic (2.03e-3)"	"unprognostic (1.61e-1)"	"unprognostic (3.13e-1)"	"unprognostic (2.18e-1)"	"unprognostic (2.13e-1)"	"unprognostic (6.84e-2)"		"unprognostic (3.07e-3)"	"unprognostic (4.31e-1)"	"unprognostic (5.88e-2)"	"unprognostic (2.50e-3)"	"unprognostic (2.14e-1)"	"unprognostic (7.26e-5)"	"unprognostic (2.29e-1)"	"unprognostic (1.57e-1)"	"unprognostic (2.35e-1)"	"unprognostic (1.14e-1)"	1.6	35.0	16.3	1.7	20.5	1.3	1.3	7.7	27.8	2.9	4.2	1.6	0.0	6.2	0.9	1.2	2.1	2.0	1.4	3.1	18.0	11.1	1.1	1.0	2.2	0.8	4.1	16.2	11.6	23.7	0.9	1.7	1.5	9.0	1.3	2.8	16.6	2.7	2.3	1.0	16.6	3.3	1.3	5.4	0.9	11.9	4.7	3.8	0.0	79.5	0.0	0.9	1.9	1.8	0.0	0.0	2.2	0.0	0.0	0.0	0.0	0.0	0.0	35.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	4.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	9.4	0.1	0.0	0.0	1.5	0.0	0.0	0.0	0.1	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	2.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	16.3	20.5	7.7	27.8	18.0	11.1	4.1	16.2	9.0	3.8
PENK		ENSG00000181195	Proenkephalin	P01210	8	56436674-56446734	"Plasma proteins, Predicted secreted proteins, Transporters"		"Endorphin, Neuropeptide, Opioid peptide"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	5	"adrenal gland: 124.3;brain: 171.5"	"Cell line enhanced"	"Detected in some"		"ASC diff: 16.2;ASC TERT1: 9.7;BJ: 9.0;THP-1: 8.4"	"Cancer enhanced"	"Detected in many"		"lung cancer: 4.5"	"Region enriched"	"Detected in many"	12	"basal ganglia: 171.5"	"Cell type enhanced"	"Detected in some"		"naive B-cell: 3.1"	"Group enriched"	"Detected in many"	19	"B-cells: 3.1;dendritic cells: 1.2;monocytes: 1.2"	"Region enriched"	"Detected in all"	7	"basal ganglia: 3244.3"	"Region enriched"	"Detected in many"	7	"basal ganglia: 1049.6"	"HPA013138, CAB016390"	Enhanced				"Secreted in other tissues"		35000			"CAB016390: AB_2161515, HPA013138: AB_1855191"	"unprognostic (6.89e-2)"	"unprognostic (1.21e-1)"	"unprognostic (2.71e-2)"	"unprognostic (1.17e-3)"	"unprognostic (1.56e-2)"	"unprognostic (3.58e-3)"		"unprognostic (1.31e-2)"	"unprognostic (3.60e-1)"	"unprognostic (6.34e-2)"	"unprognostic (5.73e-2)"	"unprognostic (3.47e-2)"	"unprognostic (4.24e-2)"	"unprognostic (1.73e-3)"	"unprognostic (1.11e-1)"	"unprognostic (4.48e-2)"	"unprognostic (3.98e-3)"	2.5	124.3	2.8	1.7	171.5	0.3	0.9	3.9	7.8	14.3	2.2	0.9	0.1	0.6	3.0	0.9	0.9	2.6	4.0	9.1	1.2	9.1	0.3	0.2	1.0	0.3	2.5	0.4	8.2	0.6	0.2	1.5	1.1	8.4	11.7	0.9	2.2	0.9	8.1	1.1	0.5	0.9	1.7	7.0	0.3	1.1	29.9	14.7	0.0	0.6	0.3	0.3	0.5	0.6	3.1	1.2	0.0	1.2	0.0	0.0	0.5	0.0	0.0	0.1	0.0	16.2	9.7	0.0	9.0	2.9	1.6	0.5	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	2.1	0.0	0.0	0.1	0.0	0.0	0.0	0.8	0.1	0.0	0.0	0.0	0.0	8.4	0.0	0.0	0.0	0.6	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.7	0.0	0.0	0.6	0.0	0.0	0.0	0.0	1.2	3.1	0.0	0.0	0.0	0.0	1.2	0.0	0.0	0.5	2.8	171.5	3.9	7.8	1.2	9.1	2.5	0.4	8.4	14.7
PHOX2A	"ARIX, CFEOM2, FEOM2, PMX2A"	ENSG00000165462	"Paired like homeobox 2a"	O14813	11	72239077-72245664	"Disease related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, DNA-binding"	"Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"adrenal gland: 24.6;brain: 12.1;lymphoid tissue: 9.7"	"Cell line enriched"	"Detected in single"	228	"SH-SY5Y: 112.7"	"Cancer enriched"	"Detected in some"	9	"ovarian cancer: 9.3"	"Region enriched"	"Detected in single"	96	"pons and medulla: 12.1"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Region enriched"	"Detected in single"	9	"pons and medulla: 0.8"	"Low region specificity"	"Detected in some"			"HPA053810, HPA065621, HPA078004"	Enhanced		Enhanced	"Nucleoplasm,Nuclear membrane,Vesicles,Cytosol"				Nucleoplasm	"Nuclear membrane, Vesicles, Cytosol"	"HPA053810: , HPA065621: , HPA078004: "			"unprognostic (5.84e-2)"		"unprognostic (8.51e-2)"					"unprognostic (5.07e-2)"	"unprognostic (2.19e-1)"		"unprognostic (2.13e-1)"	"unprognostic (9.92e-4)"	"unprognostic (3.03e-2)"			0.4	24.6	0.0	9.7	0.0	0.0	0.0	0.0	0.1	0.2	3.3	0.5	0.0	0.4	0.1	0.0	1.4	0.1	0.3	0.1	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.3	0.0	0.8	0.0	12.1	0.9	0.7	1.7	0.7	3.7	0.0	0.0	3.2	0.3	2.1	0.1	1.6	5.2	0.0	0.0	0.0	0.0	0.0	2.6	0.6	0.0	0.0	0.0	0.2	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.1	112.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	12.1	0.0
PHOX2B	"NBPhox, Phox2b, PMX2B"	ENSG00000109132	"Paired like homeobox 2b"	Q99453	4	41744082-41748970	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, Developmental protein, DNA-binding"	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"adrenal gland: 14.5;brain: 24.8"	"Cell line enriched"	"Detected in single"	91	"SH-SY5Y: 52.3"	"Not detected"	"Not detected"			"Region enriched"	"Detected in single"	99	"pons and medulla: 24.8"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Region enriched"	"Detected in single"	17	"pons and medulla: 5.9"	"Region enriched"	"Detected in single"	38	"pons and medulla: 2.0"	"HPA074325, HPA074941"	Enhanced		Enhanced	Nucleoplasm				Nucleoplasm		"HPA074325: , HPA074941: "			"unprognostic (1.01e-1)"								"unprognostic (2.47e-1)"			"unprognostic (5.27e-2)"				0.0	14.5	0.0	2.1	0.0	0.0	0.0	0.0	0.0	0.0	5.6	0.2	0.0	0.8	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	1.4	0.0	0.0	0.0	24.8	0.2	1.4	0.8	0.0	0.0	0.0	0.0	3.2	0.5	0.4	0.0	0.9	0.1	0.0	0.1	0.0	0.0	0.0	0.6	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	52.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	24.8	0.0
PNMT	PENT	ENSG00000141744	"Phenylethanolamine N-methyltransferase"	P11086	17	39667981-39670475	"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins"	"Catecholamine biosynthesis"	"Methyltransferase, Transferase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	5	"adrenal gland: 94.6;ductus deferens: 53.7;seminal vesicle: 40.7"	"Cell line enhanced"	"Detected in some"		"HEL: 4.7;K-562: 10.2;NB-4: 20.2;NTERA-2: 3.9;SCLC-21H: 5.5;SH-SY5Y: 5.0"	"Cancer enhanced"	"Detected in many"		"cervical cancer: 27.0"	"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in some"		"gdT-cell: 2.5"	"Group enriched"	"Detected in many"	5	"B-cells: 1.0;T-cells: 2.5"	"Region enhanced"	"Detected in some"		"basal ganglia: 1.3"	"Low region specificity"	"Detected in single"			"CAB017029, HPA043412, HPA051005"	Enhanced									"CAB017029: , HPA043412: AB_2630373, HPA051005: AB_2681306"	"unprognostic (1.50e-1)"	"unprognostic (3.74e-2)"	"unprognostic (1.08e-1)"	"prognostic unfavourable (3.95e-5)"	"unprognostic (4.27e-2)"	"unprognostic (3.02e-1)"	"unprognostic (2.98e-2)"	"unprognostic (5.75e-2)"	"unprognostic (5.29e-2)"	"unprognostic (1.30e-1)"	"unprognostic (1.51e-1)"	"unprognostic (1.33e-1)"	"unprognostic (1.52e-4)"	"unprognostic (1.58e-1)"	"unprognostic (1.97e-1)"	"unprognostic (4.72e-2)"	"unprognostic (1.87e-2)"	2.3	94.6	3.9	0.8	13.8	1.6	5.4	0.9	3.0	1.3	1.9	1.5	53.7	0.9	1.0	2.7	0.9	1.9	0.8	4.9	1.7	5.4	1.0	0.7	1.6	0.8	9.1	1.5	0.9	0.7	2.4	12.9	2.4	3.6	4.3	0.7	0.9	0.7	40.7	10.5	0.8	1.0	0.8	0.7	0.9	0.9	1.3	2.7	0.0	0.7	0.8	0.7	1.3	1.7	1.0	0.0	0.3	0.3	0.0	2.5	0.3	0.0	0.0	0.5	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.2	0.5	0.2	0.0	0.1	0.1	0.0	0.0	0.0	1.4	4.7	0.1	0.4	1.9	0.0	0.0	0.1	0.0	0.0	0.0	0.0	10.2	0.0	0.0	0.0	0.0	20.2	3.9	0.0	0.1	0.0	0.3	0.0	0.0	5.5	5.0	0.0	2.1	0.1	0.2	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	2.5	0.0	0.4	1.0	0.4	1.5	0.0	0.4	0.0	0.7	0.3	0.0	0.3	0.0	0.0	0.3	3.9	13.8	0.9	3.0	1.7	5.4	9.1	1.5	3.6	2.7
PTPRN	"IA-2, ICA512"	ENSG00000054356	"Protein tyrosine phosphatase, receptor type N"	Q16849	2	219289623-219309648	"Disease related genes, Predicted intracellular proteins, Predicted membrane proteins"	"Transcription, Transcription regulation"	Receptor	"Diabetes mellitus"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 89.6;pancreas: 28.9;pituitary gland: 43.4"	"Group enriched"	"Detected in some"	8	"U-2 OS: 19.8;U-87 MG: 73.7"	"Group enriched"	"Detected in some"	12	"glioma: 5.3;pancreatic cancer: 18.4"	"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA007152, HPA007179"	Enhanced		Approved	"Endoplasmic reticulum"				"Endoplasmic reticulum"		"HPA007152: , HPA007179: AB_1079714"	"unprognostic (1.43e-1)"	"unprognostic (1.33e-4)"	"unprognostic (2.91e-3)"	"unprognostic (5.83e-3)"	"prognostic unfavourable (1.45e-7)"	"unprognostic (3.64e-2)"	"unprognostic (1.24e-4)"	"unprognostic (1.58e-3)"	"unprognostic (1.02e-1)"	"unprognostic (6.20e-4)"	"unprognostic (1.44e-2)"	"unprognostic (1.54e-1)"	"unprognostic (2.28e-10)"	"unprognostic (1.43e-2)"	"unprognostic (2.49e-1)"	"unprognostic (1.10e-2)"	"unprognostic (8.61e-2)"	1.7	22.3	19.3	4.7	35.7	1.7	1.3	17.3	89.6	1.2	2.4	2.5	0.0	2.5	1.5	1.2	1.5	1.3	1.5	1.4	21.6	40.1	1.5	1.2	1.4	1.3	14.4	19.8	1.3	28.9	1.2	43.4	1.4	22.0	1.4	1.9	3.1	1.2	1.3	1.2	2.0	2.5	2.4	3.5	1.3	6.0	1.4	2.1	0.0	1.5	0.0	1.2	2.7	0.0	0.1	0.3	0.2	0.0	0.0	0.6	3.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.2	0.0	0.0	0.0	0.0	0.3	1.3	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.2	0.5	0.0	0.1	2.5	0.0	6.1	0.0	0.0	0.1	0.1	0.4	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	4.8	3.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	19.8	0.0	0.0	0.0	0.0	0.2	73.7	0.0	0.3	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.2	0.1	0.3	0.1	0.0	0.4	0.2	0.0	0.0	0.0	0.6	3.7	19.3	35.7	17.3	54.0	21.6	40.1	14.4	19.8	22.0	2.1
PTPRN2	"IA-2beta, ICAAR, KIAA0387, phogrin"	ENSG00000155093	"Protein tyrosine phosphatase, receptor type N2"	Q92932	7	157539056-158587788	"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins"	"Lipid metabolism, Phospholipid metabolism"	"Hydrolase, Protein phosphatase, Receptor"	"Diabetes mellitus"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 40.6;pancreas: 51.3"	"Cell line enhanced"	"Detected in some"		"AF22: 15.3;HDLM-2: 21.5;NB-4: 22.1;SCLC-21H: 12.2;SH-SY5Y: 12.4;THP-1: 10.8;U-87 MG: 15.1"	"Cancer enhanced"	"Detected in all"		"prostate cancer: 40.8"	"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"neutrophil: 14.8"	"Lineage enriched"	"Detected in all"	4	"granulocytes: 14.8"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA006900, HPA007255, HPA026656"	Enhanced		Approved	Vesicles				Vesicles		"HPA006900: AB_1079715, HPA007255: , HPA026656: AB_1855912"	"unprognostic (2.42e-1)"	"unprognostic (4.17e-2)"	"unprognostic (7.82e-2)"	"unprognostic (2.69e-2)"	"prognostic unfavourable (9.37e-5)"	"unprognostic (7.12e-3)"	"unprognostic (1.04e-1)"	"unprognostic (4.55e-2)"	"unprognostic (4.27e-2)"	"unprognostic (1.64e-1)"	"unprognostic (1.20e-2)"	"unprognostic (1.39e-1)"	"prognostic favourable (8.68e-4)"	"unprognostic (2.60e-2)"	"unprognostic (1.48e-1)"	"unprognostic (1.43e-3)"	"unprognostic (6.16e-2)"	2.1	10.5	20.1	1.7	33.9	1.0	1.1	6.2	40.6	1.7	4.6	2.9	0.0	5.1	2.0	2.9	1.5	6.9	4.7	1.9	18.2	21.3	2.0	1.2	3.1	2.1	11.3	22.3	5.8	51.3	0.5	20.0	1.5	10.3	10.2	3.7	1.5	3.4	2.6	0.8	0.7	4.2	1.6	5.3	7.7	24.2	2.2	5.2	0.0	5.6	0.3	1.7	2.8	0.6	3.4	1.3	14.8	1.1	1.5	3.5	1.1	0.0	0.2	15.3	1.1	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.9	0.0	0.6	0.2	0.0	0.4	0.0	0.0	21.5	0.2	0.0	0.0	2.5	0.6	0.0	0.0	1.1	0.2	0.0	0.1	0.0	0.0	0.1	0.0	0.2	6.3	22.1	3.0	0.7	0.0	0.7	0.1	0.0	0.0	12.2	12.4	0.0	0.0	0.0	0.0	10.8	3.2	5.0	1.9	0.0	0.3	0.1	0.0	0.0	15.1	9.0	3.6	8.7	1.1	1.6	0.9	0.1	0.3	2.3	1.5	1.1	1.3	3.4	1.4	0.9	14.8	1.5	0.0	0.2	3.5	1.1	20.1	33.9	6.2	40.6	18.2	21.3	11.3	22.3	10.3	5.2
QPCT	"GCT, QC"	ENSG00000115828	"Glutaminyl-peptide cyclotransferase"	Q16769	2	37344574-37373322	"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"		"Acyltransferase, Transferase"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"adrenal gland: 77.6;blood: 137.6"	"Cell line enhanced"	"Detected in many"		"BJ hTERT+: 17.5;SCLC-21H: 23.8;SK-MEL-30: 80.0;U-266/84: 62.5"	"Cancer enhanced"	"Detected in all"		"melanoma: 97.4"	"Low region specificity"	"Detected in many"			"Cell type enriched"	"Detected in some"	5	"neutrophil: 137.6"	"Lineage enriched"	"Detected in many"	5	"granulocytes: 137.6"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA008406	Enhanced		Approved	Cytosol	"Secreted to blood"			Cytosol		"HPA008406: AB_1855981"	"unprognostic (6.25e-3)"	"unprognostic (6.69e-2)"	"unprognostic (4.95e-2)"	"unprognostic (1.44e-1)"	"unprognostic (1.44e-2)"	"unprognostic (9.32e-2)"	"unprognostic (1.13e-3)"	"unprognostic (9.73e-2)"	"unprognostic (2.71e-3)"	"unprognostic (7.86e-2)"	"unprognostic (3.67e-2)"	"unprognostic (1.17e-1)"	"unprognostic (6.78e-2)"	"unprognostic (7.76e-3)"	"unprognostic (1.21e-1)"	"unprognostic (9.48e-3)"	"unprognostic (3.62e-3)"	3.2	77.6	4.3	5.4	5.8	17.0	6.4	1.2	11.6	9.2	11.3	2.2	1.5	2.2	6.2	43.7	2.4	1.9	5.5	2.9	6.7	17.9	12.4	1.3	6.1	7.4	3.9	5.0	1.4	5.5	9.6	31.6	7.8	5.9	3.5	4.2	21.2	14.7	2.8	4.0	14.2	2.3	3.4	3.0	8.5	3.4	2.6	0.5	2.3	1.8	4.4	4.8	7.0	2.9	0.2	10.7	137.6	29.7	0.0	0.0	12.1	0.1	7.9	0.0	0.0	1.0	2.6	0.0	1.0	17.5	1.3	2.1	0.5	1.4	0.0	0.6	5.9	0.0	0.5	0.0	2.1	0.1	15.3	3.5	0.0	1.5	0.1	0.5	0.0	1.5	0.0	9.7	0.0	5.2	0.0	0.0	0.0	0.8	0.0	0.3	0.1	0.0	0.0	0.0	0.1	8.6	2.1	23.8	0.0	1.3	0.0	80.0	0.1	0.5	3.7	0.0	0.0	0.0	0.1	3.0	62.5	0.0	5.3	0.0	0.0	0.6	29.7	0.2	0.0	3.4	0.0	0.2	0.0	0.0	10.7	0.1	0.0	0.0	137.6	0.0	0.3	0.2	0.0	12.1	4.3	5.8	1.2	11.6	6.7	17.9	3.9	5.0	5.9	0.5
REEP6	"C19orf32, DP1L1, FLJ25383, Yip2f"	ENSG00000115255	"Receptor accessory protein 6"	Q96HR9	19	1490747-1497927	"Disease related genes, Predicted membrane proteins"			"Disease mutation, Retinitis pigmentosa"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"intestine: 90.8;liver: 119.0;testis: 71.2"	"Cell line enhanced"	"Detected in many"		"CACO-2: 15.8;Hep G2: 15.0;K-562: 41.8;T-47d: 34.9"	"Cancer enhanced"	"Detected in all"		"liver cancer: 114.0"	"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in single"			"HPA003895, HPA048015"	Enhanced		Supported	"Endoplasmic reticulum"			26000	"Endoplasmic reticulum"		"HPA003895: AB_1845723, HPA048015: "	"unprognostic (1.21e-1)"	"unprognostic (1.56e-1)"	"unprognostic (7.76e-2)"	"unprognostic (1.63e-3)"	"unprognostic (3.24e-1)"	"unprognostic (2.43e-2)"	"unprognostic (1.92e-1)"	"unprognostic (6.85e-2)"	"unprognostic (7.38e-2)"	"unprognostic (4.56e-1)"	"unprognostic (1.49e-1)"	"unprognostic (1.93e-1)"	"unprognostic (1.40e-2)"	"unprognostic (2.17e-1)"	"unprognostic (8.08e-2)"	"unprognostic (2.83e-1)"	"unprognostic (5.38e-2)"	2.4	20.1	4.1	0.7	5.9	0.6	3.9	3.1	6.0	1.4	41.7	2.8	4.4	60.2	1.0	5.7	2.7	1.4	7.6	0.9	4.5	1.9	6.1	119.0	0.6	0.7	2.6	2.1	1.7	10.1	0.5	2.2	0.7	2.1	4.9	0.7	27.4	5.6	11.8	0.7	1.7	90.8	1.1	1.6	0.6	1.3	71.2	1.1	0.3	1.6	1.1	2.1	3.2	1.2	1.0	4.2	0.1	4.8	5.8	7.1	2.3	2.0	2.5	0.8	10.3	1.6	0.5	11.5	0.5	0.1	0.5	0.5	15.8	6.4	1.1	3.6	0.3	2.1	2.7	0.1	0.2	0.5	1.1	6.0	0.3	15.0	1.2	0.4	2.0	1.3	1.1	0.0	0.3	0.3	41.8	1.5	0.1	7.9	0.5	1.3	3.8	5.6	1.5	0.3	2.6	3.0	0.9	0.2	5.6	2.8	4.0	1.7	34.9	1.6	0.9	0.8	1.6	2.4	0.4	5.0	1.4	0.1	3.5	2.6	2.3	0.0	1.5	0.0	7.1	1.7	3.8	0.1	2.1	1.5	2.5	1.0	2.8	3.2	0.1	5.8	4.8	4.2	2.0	2.3	4.1	5.9	3.1	6.0	4.5	1.9	2.6	2.1	2.1	1.1
RGN	"RC, SMP30"	ENSG00000130988	Regucalcin	Q15493	X	47078355-47093314	"Enzymes, Plasma proteins, Predicted intracellular proteins"		Hydrolase		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	5	"adrenal gland: 51.0;liver: 118.8"	"Cell line enhanced"	"Detected in some"		"CACO-2: 16.1;fHDF/TERT166: 5.1;Hep G2: 24.1"	"Cancer enriched"	"Detected in many"	6	"liver cancer: 47.8"	"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in single"			"Low region specificity"	"Detected in all"			"HPA029102, HPA029103"	Enhanced		Approved	Nucleoplasm			47000	Nucleoplasm		"HPA029102: AB_10599846, HPA029103: AB_10602097"	"unprognostic (1.80e-1)"	"unprognostic (1.25e-1)"	"unprognostic (1.39e-1)"	"unprognostic (5.56e-3)"	"unprognostic (8.22e-3)"	"unprognostic (1.32e-2)"	"prognostic favourable (7.55e-4)"	"unprognostic (2.60e-3)"	"unprognostic (2.23e-2)"	"unprognostic (8.38e-2)"	"unprognostic (3.37e-2)"	"unprognostic (1.14e-2)"	"prognostic favourable (5.10e-10)"	"unprognostic (1.69e-2)"	"unprognostic (2.43e-1)"	"unprognostic (7.82e-2)"	"unprognostic (5.22e-2)"	2.6	51.0	6.7	0.6	6.5	0.4	1.5	8.4	6.2	2.8	1.9	6.2	2.5	4.5	2.3	6.1	1.5	1.7	2.0	4.5	6.1	4.2	17.6	118.8	4.9	0.7	5.9	4.5	7.5	12.7	6.2	2.5	4.2	5.0	4.8	1.1	8.4	7.5	6.3	3.8	0.6	4.6	4.9	4.4	1.1	2.9	1.5	5.2	0.0	6.5	1.6	0.6	2.1	1.6	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.1	0.0	0.0	0.2	0.4	0.3	0.6	0.0	0.0	16.1	0.0	0.0	0.8	5.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	24.1	0.8	0.1	0.0	1.2	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.1	0.0	0.6	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.1	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	6.7	6.5	8.4	6.2	6.1	4.2	5.9	4.5	5.0	5.2
RIMS2	"KIAA0751, OBOE, RAB3IP3, RIM2"	ENSG00000176406	"Regulating synaptic membrane exocytosis 2"	Q9UQ26	8	103500748-104256094	"Predicted intracellular proteins"	Differentiation			"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"adrenal gland: 51.1;brain: 28.7"	"Cell line enhanced"	"Detected in some"		"AF22: 6.0;Daudi: 11.7;RT4: 8.4;SCLC-21H: 20.7;U-2 OS: 5.5"	"Low cancer specificity"	"Detected in some"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"							"HPA046538, HPA066498, CAB079049"	Enhanced	Supported	Approved	"Plasma membrane,Cytosol"				"Plasma membrane, Cytosol"		"CAB079049: , HPA046538: , HPA066498: "	"unprognostic (2.98e-2)"	"unprognostic (7.14e-2)"	"unprognostic (4.47e-2)"	"unprognostic (5.51e-2)"	"unprognostic (2.82e-1)"	"unprognostic (7.09e-3)"	"unprognostic (2.02e-2)"	"unprognostic (1.16e-2)"	"unprognostic (7.61e-2)"	"unprognostic (8.01e-3)"	"unprognostic (1.40e-2)"	"unprognostic (6.34e-2)"	"unprognostic (1.67e-5)"	"unprognostic (8.12e-4)"	"unprognostic (1.04e-1)"	"unprognostic (1.61e-1)"	"unprognostic (9.08e-2)"	0.9	51.1	15.8	1.0	21.8	1.1	1.8	14.5	28.7	8.5	0.9	0.5	0.9	1.2	1.4	1.7	1.0	6.3	1.7	0.9	10.3	4.9	1.1	0.9	1.0	1.1	3.1	17.5	2.8	1.6	0.9	12.4	1.1	8.6	2.8	1.0	5.8	1.0	1.8	1.0	1.0	1.4	2.0	4.0	0.9	1.7	3.9	8.7	0.0	2.9	0.0	1.0	1.5	1.6	0.7	0.7	2.9	0.6	1.6	0.6	0.2	3.7	0.0	6.0	0.0	0.0	0.0	0.0	0.4	0.3	1.1	1.4	0.1	0.3	11.7	0.1	0.0	0.3	1.8	0.7	1.9	0.0	0.2	0.0	0.1	0.0	0.0	0.0	0.0	0.1	1.1	0.0	0.9	0.0	0.1	0.5	0.0	0.5	0.8	0.0	4.6	0.6	0.0	0.0	0.0	0.0	8.4	20.7	5.0	0.0	0.1	0.5	0.3	0.2	0.0	0.0	5.5	0.1	0.1	1.5	0.0	0.1	0.4	0.2	0.2	2.7	0.6	0.6	0.6	0.3	0.4	0.4	0.3	0.4	0.1	0.7	0.3	0.5	2.9	1.6	0.4	0.7	0.3	0.2	15.8	21.8	14.5	28.7	10.3	4.9	3.1	17.5	8.6	8.7
SCARB1	"CD36L1, CLA-1, CLA1, SR-BI, SRB1"	ENSG00000073060	"Scavenger receptor class B member 1"	Q8WTV0	12	124776856-124882668	"Predicted intracellular proteins, Predicted membrane proteins, Transporters"	"Host-virus interaction"	"Host cell receptor for virus entry, Receptor"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"adrenal gland: 173.1;liver: 93.7;placenta: 65.9"	"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"plasmacytoid DC: 24.9"	"Group enriched"	"Detected in many"	5	"dendritic cells: 24.9;monocytes: 6.5"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA066285, CAB070124, HPA072449"	Enhanced		Approved	Vesicles				Vesicles		"CAB070124: AB_10107658, HPA066285: , HPA072449: "	"unprognostic (9.70e-3)"	"unprognostic (4.94e-3)"	"unprognostic (1.32e-1)"	"unprognostic (4.79e-2)"	"unprognostic (1.65e-3)"	"unprognostic (4.21e-3)"	"prognostic unfavourable (1.83e-5)"	"prognostic unfavourable (4.02e-4)"	"unprognostic (2.30e-1)"	"unprognostic (1.09e-1)"	"unprognostic (1.80e-2)"	"unprognostic (4.99e-2)"	"prognostic unfavourable (1.49e-5)"	"unprognostic (3.50e-1)"	"unprognostic (1.49e-1)"	"unprognostic (1.81e-1)"	"unprognostic (4.13e-1)"	21.2	173.1	7.9	3.5	21.4	1.8	25.0	4.3	10.1	4.7	28.6	13.4	1.1	8.8	4.3	3.5	2.8	4.7	8.0	3.2	7.4	5.1	2.2	93.7	5.8	5.3	6.3	5.1	14.3	2.9	3.3	4.4	65.9	9.4	4.3	4.9	10.7	8.6	2.3	3.0	6.3	21.3	4.4	5.7	5.0	2.7	7.7	11.4	0.5	4.0	1.1	5.6	3.6	10.0	3.1	24.9	1.2	6.5	0.2	0.4	2.5	9.1	22.2	7.2	28.5	4.8	10.3	0.0	6.4	7.4	8.0	5.1	26.5	29.3	26.5	18.7	4.4	14.0	18.4	43.4	3.8	12.6	18.6	7.4	21.9	42.7	16.3	12.7	6.5	17.6	8.8	15.3	10.9	21.9	14.1	11.4	1.4	18.2	3.9	17.1	6.6	23.0	16.6	5.8	53.0	0.7	12.8	13.6	5.3	35.2	47.5	32.9	26.6	14.5	2.1	1.3	8.7	6.5	10.0	2.7	1.1	4.4	5.2	15.5	12.5	0.0	6.5	0.0	0.2	3.7	0.2	3.1	0.1	0.4	8.2	1.7	0.1	0.1	1.2	0.2	0.5	24.9	0.0	2.5	7.9	21.4	4.3	10.1	7.4	5.1	6.3	5.1	9.4	11.4
SCG2	"CHGC, SgII, SN"	ENSG00000171951	"Secretogranin II"	P13521	2	223596940-223602503	"Plasma proteins, Predicted secreted proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	6	"adrenal gland: 133.0;brain: 94.1;pituitary gland: 76.5"	"Cell line enhanced"	"Detected in some"		"ASC TERT1: 26.2;HSkMC: 22.4;SCLC-21H: 22.8;SH-SY5Y: 9.9;WM-115: 16.7"	"Group enriched"	"Detected in many"	8	"glioma: 70.0;pancreatic cancer: 52.9"	"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA011893, HPA075062"	Enhanced	Supported	Approved	"Golgi apparatus,Vesicles"	"Secreted to blood"		54000	"Golgi apparatus"	Vesicles	"HPA011893: AB_1856656, HPA075062: AB_2732277"	"unprognostic (2.93e-2)"	"unprognostic (1.44e-2)"	"unprognostic (1.23e-3)"	"unprognostic (6.82e-4)"	"unprognostic (2.51e-2)"	"unprognostic (1.13e-2)"	"unprognostic (2.77e-3)"	"unprognostic (6.73e-2)"	"unprognostic (1.08e-1)"	"unprognostic (4.69e-2)"	"prognostic favourable (5.58e-4)"	"unprognostic (1.34e-1)"	"prognostic unfavourable (7.01e-10)"	"unprognostic (2.47e-3)"	"unprognostic (4.02e-1)"	"unprognostic (1.57e-2)"	"unprognostic (1.90e-3)"	3.5	133.0	13.3	11.0	94.1	0.9	0.9	5.6	55.9	1.4	5.4	5.8	0.0	17.3	2.1	0.9	1.0	0.8	2.2	1.4	10.5	79.4	1.0	0.8	1.9	0.9	21.7	11.0	1.3	10.7	1.1	76.5	1.1	57.7	2.1	5.5	1.5	0.9	1.3	0.8	1.0	8.0	5.2	10.3	0.8	8.0	0.9	5.0	0.0	3.1	0.0	0.8	1.1	0.2	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	1.4	4.9	4.1	1.1	26.2	0.1	0.2	0.9	1.9	4.9	0.2	0.4	0.0	0.4	0.3	0.1	0.1	0.0	2.5	0.0	0.2	0.0	0.3	0.0	0.3	0.3	2.2	22.4	0.1	2.7	0.9	0.0	0.1	0.2	2.4	0.1	0.0	0.1	3.5	0.0	0.0	0.1	0.0	0.3	0.0	22.8	9.9	0.0	0.2	1.1	0.0	0.0	0.0	2.6	1.0	0.1	1.7	0.0	0.0	0.1	0.7	0.0	16.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	13.3	94.1	5.6	23.0	10.5	79.4	21.7	11.0	57.7	5.0
SLC18A1	"CGAT, VAT1, VMAT1"	ENSG00000036565	"Solute carrier family 18 member A1"	P54219	8	20144855-20183206	"FDA approved drug targets, Predicted membrane proteins, Transporters"	"Neurotransmitter transport, Transport"		"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"adrenal gland: 25.4;intestine: 10.8"	"Cell line enriched"	"Detected in some"	8	"SH-SY5Y: 38.3"	"Cancer enhanced"	"Detected in some"		"colorectal cancer: 0.8"	"Region enriched"	"Detected in single"	4	"midbrain: 2.0"	"Group enriched"	"Detected in some"	12	"intermediate monocyte: 2.3;non-classical monocyte: 6.0"	"Lineage enriched"	"Detected in single"	18	"monocytes: 6.0"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			"HPA006877, HPA063797"	Enhanced									"HPA006877: , HPA063797: AB_2685125"	"unprognostic (8.03e-4)"	"unprognostic (1.02e-1)"	"unprognostic (3.75e-3)"	"unprognostic (3.50e-1)"	"unprognostic (6.61e-2)"	"unprognostic (3.09e-3)"	"unprognostic (1.67e-1)"	"unprognostic (2.16e-2)"	"unprognostic (3.45e-2)"	"unprognostic (1.48e-1)"	"unprognostic (1.32e-3)"	"unprognostic (1.61e-1)"	"unprognostic (2.48e-2)"	"unprognostic (8.25e-2)"	"unprognostic (4.41e-2)"	"unprognostic (2.06e-1)"	"unprognostic (1.05e-1)"	0.0	25.4	0.2	0.8	0.1	0.0	0.0	0.0	0.2	0.2	8.8	1.3	1.3	1.4	0.4	0.0	0.0	0.0	0.7	0.1	0.1	0.4	0.0	0.0	0.0	0.0	2.0	0.0	0.2	0.0	0.0	0.0	0.0	0.4	1.0	2.7	0.0	0.0	2.8	0.0	0.0	10.8	0.0	0.1	0.3	1.1	0.2	0.0	0.2	0.2	0.0	0.1	1.3	0.4	0.0	0.3	0.2	6.0	0.0	0.0	0.3	0.0	0.0	1.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	4.5	0.0	0.0	0.0	2.2	38.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	2.3	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.2	0.0	6.0	0.0	0.0	0.3	0.2	0.1	0.0	0.2	0.1	0.4	2.0	0.0	0.4	0.0
SLC18A2	"SVAT, SVMT, VMAT2"	ENSG00000165646	"Solute carrier family 18 member A2"	Q05940	10	117241073-117279430	"FDA approved drug targets, Predicted membrane proteins, Transporters"	"Neurotransmitter transport, Transport"		"Disease mutation, Dystonia, FDA approved drug targets, Parkinsonism"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 26.3;brain: 28.3;cervix, uterine: 31.2"	"Cell line enriched"	"Detected in some"	20	"HMC-1: 89.0"	"Low cancer specificity"	"Detected in some"			"Group enriched"	"Detected in many"	10	"hypothalamus: 9.0;midbrain: 28.3;pons and medulla: 26.5"	"Cell type enriched"	"Detected in some"	13	"basophil: 26.3"	"Lineage enriched"	"Detected in many"	13	"granulocytes: 26.3"	"Region enhanced"	"Detected in many"		"midbrain: 75.4"	"Group enriched"	"Detected in all"	5	"midbrain: 143.8;pons and medulla: 34.7"	HPA073224	Enhanced		Supported	Vesicles,Centrosome				Vesicles	Centrosome	"HPA073224: "	"unprognostic (1.49e-1)"	"unprognostic (2.48e-1)"	"unprognostic (2.33e-3)"	"unprognostic (9.00e-2)"	"unprognostic (2.85e-1)"	"unprognostic (5.33e-3)"	"unprognostic (2.23e-1)"	"unprognostic (1.71e-2)"	"unprognostic (1.40e-1)"	"unprognostic (4.55e-2)"	"unprognostic (2.00e-1)"	"unprognostic (6.06e-3)"	"unprognostic (7.94e-5)"	"unprognostic (2.95e-2)"	"unprognostic (2.31e-1)"	"unprognostic (2.43e-1)"	"unprognostic (3.57e-2)"	1.7	13.9	1.7	3.1	2.0	2.0	2.0	1.7	1.6	31.2	2.3	0.5	2.2	1.5	11.2	4.9	3.0	1.1	15.9	1.0	1.9	9.0	1.1	3.3	7.6	1.5	28.3	0.2	9.7	3.7	0.5	1.6	2.1	26.5	10.8	3.4	3.1	1.0	4.0	1.1	5.8	2.5	5.4	2.9	0.5	3.5	1.5	0.3	14.1	0.6	3.4	2.9	3.1	5.4	0.0	2.0	26.3	0.0	0.0	0.3	1.1	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.1	4.5	0.0	0.0	0.0	0.2	89.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.2	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.9	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.2	0.1	0.1	0.0	0.1	0.4	0.0	26.3	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.3	0.2	0.0	0.0	2.0	0.0	1.1	1.7	2.0	1.7	1.6	1.9	9.0	28.3	0.2	26.5	0.3
SLC6A2	"NAT1, NET, NET1, SLC6A5"	ENSG00000103546	"Solute carrier family 6 member 2"	P23975	16	55655604-55706192	"Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters"	"Neurotransmitter transport, Symport, Transport"		"Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"adrenal gland: 20.4;placenta: 41.8"	"Cell line enriched"	"Detected in some"	30	"SH-SY5Y: 104.5"	"Cancer enhanced"	"Detected in some"		"liver cancer: 1.9"	"Region enriched"	"Detected in single"	27	"pons and medulla: 9.7"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Region enriched"	"Detected in some"	4	"pons and medulla: 8.2"	"Region enriched"	"Detected in single"	32	"pons and medulla: 23.1"	"HPA004057, HPA076311, CAB078195"	Enhanced	Supported	Approved	Mitochondria,Cytosol				Cytosol	Mitochondria	"CAB078195: , HPA004057: AB_1080012, HPA076311: "	"unprognostic (9.58e-3)"	"unprognostic (5.48e-2)"		"unprognostic (1.26e-4)"	"unprognostic (4.07e-1)"	"unprognostic (4.16e-1)"	"unprognostic (8.38e-2)"	"unprognostic (2.97e-2)"	"unprognostic (3.29e-1)"	"unprognostic (2.31e-1)"	"unprognostic (3.27e-1)"	"unprognostic (2.12e-2)"	"unprognostic (2.95e-2)"	"unprognostic (1.72e-1)"	"unprognostic (6.02e-2)"	"unprognostic (8.48e-2)"	"unprognostic (1.43e-2)"	2.4	20.4	0.3	0.1	0.1	0.0	1.8	0.1	0.3	3.2	0.3	0.3	0.1	0.0	4.5	7.2	0.8	0.4	0.4	0.1	0.1	0.0	0.4	1.0	0.5	0.1	0.1	0.1	0.2	0.1	0.0	0.1	41.8	9.7	0.5	0.1	0.1	1.6	1.7	0.1	11.4	0.4	1.0	0.2	0.1	0.2	8.3	0.2	0.1	0.2	0.9	0.5	0.5	1.7	0.0	0.2	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	1.0	0.8	104.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.1	0.1	0.3	0.1	0.0	0.1	0.1	9.7	0.2
SOAT1	"ACAT, SOAT, STAT"	ENSG00000057252	"Sterol O-acyltransferase 1"	P35610	1	179293714-179358680	"Enzymes, FDA approved drug targets, Predicted membrane proteins"	"Cholesterol metabolism, Lipid metabolism, Steroid metabolism, Sterol metabolism"	"Acyltransferase, Transferase"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"adrenal gland: 87.4"	"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB009533, HPA047171"	Enhanced		Enhanced	"Endoplasmic reticulum"				"Endoplasmic reticulum"		"CAB009533: AB_633499, HPA047171: "	"unprognostic (3.29e-2)"	"unprognostic (7.60e-2)"	"unprognostic (1.11e-1)"	"unprognostic (3.21e-2)"	"unprognostic (2.83e-1)"	"unprognostic (1.81e-3)"	"unprognostic (7.81e-3)"	"unprognostic (3.29e-1)"	"unprognostic (9.00e-2)"	"unprognostic (9.84e-2)"	"unprognostic (1.06e-1)"	"unprognostic (5.45e-3)"	"unprognostic (7.02e-3)"	"unprognostic (4.67e-3)"	"unprognostic (9.64e-2)"	"unprognostic (4.67e-2)"	"unprognostic (1.82e-1)"	23.9	87.4	4.1	8.3	5.7	7.0	9.6	2.9	4.0	6.8	7.2	5.6	7.8	5.5	8.2	6.0	3.4	8.3	9.8	5.7	5.5	4.1	12.1	8.8	18.6	13.0	6.2	2.3	10.8	15.5	8.1	14.6	11.6	4.9	13.1	6.9	9.6	51.1	8.9	4.1	5.8	7.0	7.5	10.5	13.6	8.1	6.8	4.9	4.0	6.2	2.9	7.2	9.4	8.7	6.6	24.3	19.8	26.8	18.5	16.0	14.8	20.2	9.5	7.8	11.6	30.5	16.7	42.0	9.8	17.3	21.7	25.5	9.7	23.2	11.5	15.5	17.8	7.5	24.9	5.8	23.5	13.1	5.1	5.3	8.0	10.1	12.5	9.1	2.1	13.2	3.8	25.4	21.8	9.3	11.4	5.9	33.8	4.3	9.6	2.9	3.8	3.1	12.1	10.1	6.7	19.2	12.7	2.4	6.1	15.1	6.4	5.6	6.7	6.3	8.8	25.9	12.4	28.3	21.5	8.4	30.6	9.8	10.3	4.9	48.0	19.6	26.8	0.7	14.0	17.0	13.5	6.6	13.1	13.1	24.3	5.5	12.7	12.6	19.8	18.5	11.1	4.4	16.0	14.8	4.1	5.7	2.9	4.0	5.5	4.1	6.2	2.3	4.9	4.9
SPTBN4	"KIAA1642, SPTBN3"	ENSG00000160460	"Spectrin beta, non-erythrocytic 4"	Q9H254	19	40466241-40576464	"Disease related genes, Plasma proteins, Predicted intracellular proteins"		"Actin capping, Actin-binding"	"Deafness, Disease mutation, Neuropathy"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	4	"brain: 36.3"	"Cell line enhanced"	"Detected in some"		"K-562: 3.5;Karpas-707: 5.0;SCLC-21H: 7.9;SH-SY5Y: 4.8"	"Low cancer specificity"	"Detected in some"			"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA054481	Enhanced		Approved	Nucleoplasm,Nucleoli				Nucleoli	Nucleoplasm	"HPA054481: "	"unprognostic (1.97e-3)"	"unprognostic (1.02e-1)"	"unprognostic (5.65e-4)"	"unprognostic (3.72e-4)"	"unprognostic (7.79e-3)"	"unprognostic (9.77e-2)"	"unprognostic (2.62e-1)"	"unprognostic (2.50e-2)"	"unprognostic (3.19e-2)"	"unprognostic (1.65e-1)"	"unprognostic (1.78e-4)"	"unprognostic (4.54e-1)"	"unprognostic (2.55e-2)"	"unprognostic (6.79e-2)"	"unprognostic (1.42e-1)"	"unprognostic (1.85e-2)"	"unprognostic (2.02e-1)"	3.1	5.9	13.4	1.2	15.3	1.2	1.2	36.3	27.1	1.4	1.3	1.8	0.0	1.7	2.3	1.3	1.6	2.0	1.8	3.3	9.8	10.8	1.9	1.3	1.2	1.0	7.5	13.0	4.1	3.0	3.3	8.0	1.0	10.4	2.8	1.1	2.6	2.2	2.0	5.1	1.3	1.5	1.8	2.8	1.3	2.5	3.5	3.7	0.0	1.6	0.0	1.0	1.2	0.5	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	1.5	0.0	0.2	0.1	0.0	0.0	0.2	0.0	0.1	0.1	0.0	0.4	2.3	1.9	0.4	0.0	0.0	0.0	0.0	0.4	2.3	0.5	0.0	0.0	0.3	0.0	0.8	0.3	0.0	0.0	0.0	0.0	3.5	5.0	0.0	1.3	0.0	0.0	0.2	0.8	0.5	0.0	1.1	0.0	0.0	7.9	4.8	0.1	0.2	0.0	0.7	0.0	0.0	0.0	1.4	0.8	0.0	0.2	0.3	0.3	0.1	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	13.4	15.3	36.3	22.7	9.8	10.8	7.5	13.0	10.4	3.7
SST	SMST	ENSG00000157005	Somatostatin	P61278	3	187668906-187670399	"Cancer-related genes, Plasma proteins, Predicted secreted proteins"		Hormone	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	5	"brain: 102.8;intestine: 105.2;pancreas: 105.6;stomach 1: 90.4"	"Cell line enhanced"	"Detected in some"		"EFO-21: 15.2;U-2 OS: 28.3;U-251 MG: 4.7;U-698: 5.9"	"Group enriched"	"Detected in many"	7	"ovarian cancer: 249.9;pancreatic cancer: 1039.3"	"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"CAB000075, HPA019472, CAB034105"	Enhanced	Supported			"Secreted to blood"					"CAB000075: AB_2688022, CAB034105: AB_2271061, HPA019472: AB_1857360"		"unprognostic (2.44e-1)"	"unprognostic (2.05e-1)"	"prognostic unfavourable (1.93e-5)"	"unprognostic (5.12e-3)"	"unprognostic (1.54e-2)"			"unprognostic (4.69e-1)"	"unprognostic (3.31e-2)"	"unprognostic (8.16e-3)"	"unprognostic (1.63e-1)"	"unprognostic (1.07e-3)"	"unprognostic (8.47e-2)"	"unprognostic (4.19e-1)"	"unprognostic (3.27e-1)"	"unprognostic (1.45e-1)"	2.0	13.0	28.6	1.9	53.8	1.7	0.7	0.1	47.9	0.7	45.1	1.8	21.9	105.2	0.9	0.7	1.1	0.7	1.0	0.9	17.5	102.8	2.5	0.7	0.7	1.0	6.2	15.4	0.8	105.6	0.7	1.5	0.7	16.1	1.5	7.4	0.4	0.7	7.5	0.7	3.1	36.1	1.4	18.4	0.7	90.4	0.7	8.6	0.0	0.9	0.0	0.7	4.6	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	15.2	0.0	0.0	0.0	0.0	0.0	1.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.2	0.3	0.0	0.0	0.0	0.0	0.1	0.0	0.0	28.3	0.3	4.7	0.0	1.6	5.9	0.1	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	28.6	53.8	0.1	47.9	17.5	102.8	6.2	15.4	16.1	8.6
STAR	"StAR, STARD1"	ENSG00000147465	"Steroidogenic acute regulatory protein"	P49675	8	38143649-38151265	"Disease related genes, Predicted intracellular proteins"	"Lipid transport, Steroidogenesis, Transport"		"Congenital adrenal hyperplasia, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	7	"adrenal gland: 311.3;ovary: 124.6"	"Cell line enriched"	"Detected in some"	5	"K-562: 99.5"	"Cancer enhanced"	"Detected in some"		"testis cancer: 3.0"	"Region enriched"	"Detected in some"	8	"basal ganglia: 10.6"	"Cell type enriched"	"Detected in single"	11	"basophil: 5.7"	"Lineage enriched"	"Detected in single"	11	"granulocytes: 5.7"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA023644, HPA027318, CAB032598"	Enhanced									"CAB032598: AB_2115937, HPA023644: AB_10598916, HPA027318: AB_10601574"	"unprognostic (1.60e-4)"	"unprognostic (3.20e-2)"	"unprognostic (9.17e-2)"	"unprognostic (3.28e-2)"	"unprognostic (9.22e-2)"	"unprognostic (1.32e-3)"	"unprognostic (1.96e-2)"	"unprognostic (2.12e-5)"	"unprognostic (3.30e-2)"	"unprognostic (2.36e-1)"	"unprognostic (1.77e-3)"	"unprognostic (6.65e-2)"	"unprognostic (4.75e-9)"	"unprognostic (1.58e-1)"	"unprognostic (1.33e-1)"	"unprognostic (9.48e-2)"	"unprognostic (6.16e-2)"	0.2	311.3	0.5	0.3	10.6	0.3	0.0	0.0	1.0	0.0	0.0	11.6	0.0	0.0	0.1	0.8	0.2	0.4	0.0	0.1	0.3	0.5	0.0	0.0	0.0	0.3	0.2	0.9	124.6	0.0	0.0	0.2	0.0	1.2	0.0	0.0	0.0	0.1	0.0	0.0	0.5	0.0	0.2	0.4	0.0	0.0	29.5	0.1	0.0	0.0	0.0	0.2	0.0	0.2	0.3	0.1	5.7	0.1	0.0	0.5	0.1	0.0	0.0	0.2	0.0	0.0	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	21.4	0.1	1.3	0.3	1.0	0.0	3.4	0.0	0.0	0.0	0.0	99.5	0.0	0.0	0.0	0.0	11.7	2.7	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.2	0.0	0.0	0.0	0.0	11.9	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.5	0.0	5.7	0.1	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.3	0.0	0.2	0.3	0.0	0.0	0.0	0.5	0.1	0.5	10.6	0.0	1.0	0.3	0.5	0.2	0.9	1.2	0.1
TH	DYT5b	ENSG00000180176	"Tyrosine hydroxylase"	P07101	11	2163929-2171877	"Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins"	"Catecholamine biosynthesis, Neurotransmitter biosynthesis"	"Monooxygenase, Oxidoreductase"	"Disease mutation, Dystonia, FDA approved drug targets, Parkinson disease, Parkinsonism"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	31	"adrenal gland: 83.5;brain: 41.4"	"Group enriched"	"Detected in some"	32	"PC-3: 35.1;SK-BR-3: 12.5"	"Cancer enhanced"	"Detected in some"		"urothelial cancer: 4.0"	"Group enriched"	"Detected in many"	6	"hypothalamus: 15.5;midbrain: 41.4;pons and medulla: 41.2"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Region enhanced"	"Detected in many"		"olfactory region: 220.1"	"Region enriched"	"Detected in many"	19	"midbrain: 692.0"	"CAB002522, HPA013768, HPA014010, HPA061003, CAB072340"	Enhanced	Supported	Approved	Cytosol				Cytosol		"CAB002522: AB_564047, CAB072340: , HPA013768: , HPA014010: , HPA061003: "	"unprognostic (1.31e-1)"	"unprognostic (1.30e-1)"	"unprognostic (9.08e-2)"	"unprognostic (1.75e-4)"	"unprognostic (8.82e-3)"	"unprognostic (5.88e-2)"	"unprognostic (1.93e-1)"	"unprognostic (1.74e-3)"	"unprognostic (3.83e-2)"	"unprognostic (4.39e-4)"	"unprognostic (4.97e-1)"	"unprognostic (3.61e-2)"	"unprognostic (1.92e-1)"	"unprognostic (1.60e-1)"	"unprognostic (2.43e-1)"	"unprognostic (2.70e-2)"	"unprognostic (2.18e-2)"	1.3	83.5	0.0	0.3	5.4	0.2	0.2	0.0	0.7	1.8	0.2	6.2	0.0	0.2	0.3	0.3	0.2	0.3	0.4	0.2	0.3	15.5	0.2	0.2	0.2	0.2	41.4	0.0	0.3	0.3	0.2	0.2	0.9	41.2	0.6	0.2	0.3	0.2	2.0	0.2	0.5	0.4	0.2	0.0	0.3	0.2	0.3	1.5	0.0	0.2	0.0	0.2	0.9	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	35.1	0.0	0.0	0.0	0.1	0.0	0.6	0.1	0.0	12.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.4	0.0	0.7	0.3	15.5	41.4	0.0	41.2	1.5
VAT1L	KIAA1576	ENSG00000171724	"Vesicle amine transport 1 like"	Q9HCJ6	16	77788530-77980107	"Plasma proteins, Predicted intracellular proteins"		Oxidoreductase		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"adrenal gland: 57.3;brain: 47.1;retina: 32.1"	"Cell line enhanced"	"Detected in some"		"AF22: 9.2;BJ hTERT+: 27.1;fHDF/TERT166: 14.8;NTERA-2: 31.9;U-87 MG: 33.5"	"Cancer enhanced"	"Detected in many"		"glioma: 7.6"	"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in single"		"myeloid DC: 1.1"	"Lineage enhanced"	"Detected in single"		"dendritic cells: 1.1"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA044061, CAB046032, HPA061138"	Enhanced		Approved	Cytosol				Cytosol		"CAB046032: AB_11126308, HPA044061: AB_10959610, HPA061138: "	"unprognostic (1.49e-2)"	"unprognostic (8.74e-3)"	"unprognostic (8.80e-3)"	"unprognostic (3.39e-2)"	"unprognostic (3.62e-2)"	"unprognostic (1.70e-2)"	"unprognostic (2.39e-3)"	"unprognostic (1.37e-1)"	"unprognostic (1.86e-1)"	"unprognostic (7.65e-2)"	"unprognostic (8.57e-3)"	"unprognostic (2.46e-1)"	"prognostic unfavourable (3.01e-6)"	"unprognostic (2.50e-2)"	"unprognostic (6.53e-2)"	"unprognostic (1.19e-1)"	"unprognostic (5.96e-2)"	1.1	57.3	7.9	3.0	41.3	1.2	1.0	28.4	20.1	1.3	3.4	5.7	0.0	2.4	1.8	6.3	2.0	1.4	3.8	12.7	3.8	47.1	5.3	1.4	0.9	1.0	8.4	12.7	0.9	2.1	0.6	1.5	2.0	27.2	0.8	5.2	32.1	0.9	1.0	0.6	0.6	3.1	2.6	15.4	0.7	1.7	2.1	5.8	0.0	2.0	0.0	2.4	1.4	0.4	0.4	1.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	9.2	0.0	3.2	0.0	0.0	1.1	27.1	0.3	0.2	0.0	0.0	0.0	0.0	14.8	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.3	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.1	31.9	0.0	0.7	0.0	0.0	0.0	0.0	1.2	1.5	0.0	0.4	0.0	0.0	7.2	0.0	0.0	3.5	0.0	0.0	0.0	0.0	0.0	33.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	7.9	41.3	28.4	9.1	3.8	47.1	8.4	12.7	27.2	5.8
VGF	"SCG7, SgVII"	ENSG00000128564	"VGF nerve growth factor inducible"	O15240	7	101162509-101165593	"Plasma proteins, Predicted secreted proteins"		"Antibiotic, Antimicrobial, Growth factor"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	7	"brain: 59.4;pituitary gland: 30.4"	"Cell line enhanced"	"Detected in some"		"SH-SY5Y: 35.9;SK-MEL-30: 96.8;U-2 OS: 17.6;WM-115: 29.0"	"Cancer enriched"	"Detected in many"	6	"melanoma: 236.3"	"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"HPA055177, HPA072505"	Enhanced		Supported	"Golgi apparatus,Vesicles"	"Secreted to blood"	1273770	2800000	"Golgi apparatus, Vesicles"		"HPA055177: AB_2682728, HPA072505: AB_2686528"	"unprognostic (3.04e-2)"	"unprognostic (3.45e-1)"	"unprognostic (3.19e-3)"	"prognostic unfavourable (4.25e-4)"	"prognostic unfavourable (3.31e-4)"	"unprognostic (1.51e-2)"	"unprognostic (2.86e-2)"	"unprognostic (1.66e-3)"	"unprognostic (2.25e-2)"	"unprognostic (8.77e-2)"	"unprognostic (3.84e-3)"	"unprognostic (3.70e-3)"	"unprognostic (9.82e-3)"	"unprognostic (3.79e-1)"	"unprognostic (7.23e-2)"	"unprognostic (4.36e-3)"	"unprognostic (2.21e-1)"	3.8	3.1	10.9	2.3	25.2	1.3	1.1	1.3	59.4	1.1	1.5	1.3	0.0	1.3	2.2	1.1	1.1	1.1	1.2	1.2	12.2	51.0	1.4	1.1	1.1	1.1	3.9	22.8	1.1	6.2	1.1	30.4	1.2	41.2	1.2	1.2	0.5	1.1	1.1	1.1	1.4	1.3	1.5	6.6	1.2	3.6	1.4	0.5	0.0	1.2	0.0	1.2	1.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.2	0.2	1.9	0.0	0.0	2.1	0.1	0.0	0.0	0.0	0.4	0.1	0.0	0.6	0.0	0.2	0.1	0.0	0.0	0.1	0.1	0.0	0.0	0.1	0.0	0.1	0.9	0.0	0.0	0.0	0.1	0.0	0.7	0.4	0.0	4.6	0.0	0.4	3.6	0.4	0.1	0.0	0.0	0.0	0.0	2.9	35.9	0.0	0.1	96.8	0.0	0.0	0.0	0.0	17.6	0.0	0.4	0.0	0.1	0.9	2.8	0.0	29.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	10.9	25.2	1.3	59.4	12.2	51.0	3.9	22.8	41.2	0.5
ZBTB8B	"DKFZp547H154, RP1-27O5.1, ZNF916B"	ENSG00000273274	"Zinc finger and BTB domain containing 8B"	Q8NAP8	1	32465069-32496686	"Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	DNA-binding		"Evidence at protein level"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"pituitary gland: 10.8"	"Cell line enhanced"	"Detected in some"		"RT4: 3.7;SCLC-21H: 3.6"	"Cancer enhanced"	"Detected in single"		"testis cancer: 0.5"	"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"											HPA055553	Enhanced									"HPA055553: "	"unprognostic (8.32e-4)"	"unprognostic (1.23e-1)"	"unprognostic (3.83e-1)"	"unprognostic (3.83e-5)"	"unprognostic (1.86e-2)"	"unprognostic (5.65e-2)"	"unprognostic (1.67e-4)"	"unprognostic (1.57e-2)"	"unprognostic (5.94e-2)"	"unprognostic (3.43e-3)"	"unprognostic (9.08e-3)"	"unprognostic (1.35e-1)"	"unprognostic (2.93e-2)"	"unprognostic (3.44e-2)"	"unprognostic (6.11e-2)"	"unprognostic (3.26e-3)"	"unprognostic (5.88e-3)"	0.4	1.3	5.1	0.6	2.8	2.5	0.6	2.2	5.0	0.4	0.3	1.3	0.7	0.5	1.2	1.3	0.7	0.7	0.6	0.4	3.3	4.7	0.6	0.6	0.5	0.9	2.6	2.7	1.0	0.8	1.0	10.8	0.7	4.1	0.8	0.4	0.2	1.7	0.5	3.4	1.7	0.5	0.5	1.6	0.8	0.5	3.1	1.6	0.0	0.8	0.0	0.6	1.0	0.4	1.4	1.2	3.2	0.8	1.3	0.7	0.2	0.2	0.1	2.0	1.5	0.2	0.5	0.6	0.2	0.1	0.7	0.6	0.2	0.5	0.4	0.7	0.1	0.7	2.3	0.2	0.5	0.7	2.5	0.3	0.7	0.4	0.0	0.3	0.4	0.2	0.2	0.5	0.0	0.2	0.2	0.9	0.1	0.3	0.3	0.6	2.1	0.9	0.3	0.2	0.3	0.4	3.7	3.6	2.2	1.3	0.5	0.2	0.4	0.3	0.9	0.5	0.4	0.6	0.3	0.7	0.7	0.4	0.5	0.4	0.4	3.2	0.8	1.0	0.6	0.5	0.6	0.8	0.6	0.5	0.3	1.4	0.7	0.7	2.9	1.3	0.7	1.2	0.5	0.2	5.1	2.8	2.2	5.0	3.3	4.7	2.6	2.7	4.1	1.6